<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:NAOV="http://nanovibronix.com/20231231"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="naov-20231231.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2024-04-08</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SaleOfEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">NAOV:SaleOfEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-02-082023-02-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2023-02-08</startDate>
            <endDate>2023-02-08</endDate>
        </period>
    </context>
    <context id="From2023-02-152023-02-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-16</endDate>
        </period>
    </context>
    <context id="From2022-11-282022-11-29_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-28</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-29_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-29</instant>
        </period>
    </context>
    <context id="From2022-10-052022-10-06_custom_HCWainwrightAndCoLLCMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-05</startDate>
            <endDate>2022-10-06</endDate>
        </period>
    </context>
    <context id="From2022-10-052022-10-06_custom_HCWainwrightAndCoLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-05</startDate>
            <endDate>2022-10-06</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-06_custom_HCWainwrightAndCoLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-06</instant>
        </period>
    </context>
    <context id="From2023-08-302023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-30</startDate>
            <endDate>2023-08-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-30</startDate>
            <endDate>2023-08-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A2WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A2WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-30</startDate>
            <endDate>2023-08-30</endDate>
        </period>
    </context>
    <context id="From2023-08-302023-08-30_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-30</startDate>
            <endDate>2023-08-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-05_custom_WainwrightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:WainwrightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-05</instant>
        </period>
    </context>
    <context id="From2023-07-052023-07-05_custom_WainwrightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:WainwrightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-05</startDate>
            <endDate>2023-07-05</endDate>
        </period>
    </context>
    <context id="From2022-09-122022-09-13_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-12</startDate>
            <endDate>2022-09-13</endDate>
        </period>
    </context>
    <context id="From2022-09-122022-09-13_custom_SeriesFCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesFCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-12</startDate>
            <endDate>2022-09-13</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandFourteenLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NAOV:TwoThousandFourteenLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-02-092023-02-09_custom_TwoThousandFourteenLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NAOV:TwoThousandFourteenLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-09</startDate>
            <endDate>2023-02-09</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandFourteenLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">NAOV:TwoThousandFourteenLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2022-06-14</instant>
        </period>
    </context>
    <context id="From2022-06-132022-06-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2022-06-13</startDate>
            <endDate>2022-06-14</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-09-292022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2022-09-29</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2022-11-29</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_A1WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="From2023-08-302023-08-30_custom_A1WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-30</startDate>
            <endDate>2023-08-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_A2WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A2WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="From2023-08-302023-08-30_custom_A2WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A2WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-30</startDate>
            <endDate>2023-08-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_WainwrightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:WainwrightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="From2023-08-302023-08-30_custom_WainwrightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:WainwrightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-30</startDate>
            <endDate>2023-08-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_StockOptionsEmployeeAndNonEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NAOV:StockOptionsEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_StockOptionsEmployeeAndNonEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NAOV:StockOptionsEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_AU">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_AU">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_IL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_IL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_country_IN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_IN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_OtherCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_OtherCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:LicensingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-09</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">NAOV:PriceAtValuationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">NAOV:PriceAtValuationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_DerivativeLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DerivativeLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_DerivativeLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_DerivativeLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_DerivativeLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2021-02-252021-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-02-26</endDate>
        </period>
    </context>
    <context id="From2022-03-142022-03-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2022-03-14</startDate>
            <endDate>2022-03-15</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ArbitratorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:ArbitratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ArbitratorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:ArbitratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-01_custom_LeaseAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">NAOV:LeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-01</instant>
        </period>
    </context>
    <context id="From2024-03-012024-03-01_custom_LeaseAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">NAOV:LeaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-01</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-01_us-gaap_SubsequentEventMember_custom_VeranexIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:VeranexIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-01</instant>
        </period>
    </context>
    <context id="From2024-03-012024-03-01_us-gaap_SubsequentEventMember_custom_VeranexIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:VeranexIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-01</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-12-31" id="Fact000005">0001326706</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0126"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0127"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0132"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0133"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0151"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0152"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0170"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0171"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0189"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0190"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0208"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0209"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0325"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0327"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0329"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0331"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:IssuanceOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:IssuanceOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:IssuanceOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:IssuanceOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:IssuanceOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:IssuanceOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:IssuanceOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:IssuanceOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:IssuanceOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:RedemptionOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:RedemptionOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:RedemptionOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:RedemptionOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:RedemptionOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:RedemptionOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:RedemptionOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:RedemptionOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:RedemptionOfRedeemableSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0425"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0427"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0429"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0431"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0445"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0447"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0449"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0451"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0466"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0494"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0503"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0504"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0505"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0506"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0507"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0508"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0509"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0510"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0511"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0516"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0518"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0519"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0520"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0522"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0527"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0528"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0530"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0535"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0536"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0538"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0545"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0547"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0549"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0551"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0555"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0556"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0557"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0565"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0567"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0569"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0571"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0659"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0660"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0662"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0663"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:ExchangeOfCommonStocksIntoPreferredStock
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0668"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:ExchangeOfCommonStocksIntoPreferredStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0669"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:SharesIssuedFromExerciseOfWarrantsPreviouslyClassifiedAsDerivativeLiability
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0671"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:SharesIssuedFromExerciseOfWarrantsPreviouslyClassifiedAsDerivativeLiability
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0672"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:ReclassDerivativeLiabilityToEquityDueToIncreaseInAuthorizedShares
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0674"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:ReclassDerivativeLiabilityToEquityDueToIncreaseInAuthorizedShares
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0675"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:ReclassLiabilityToEquityAfterIncreaseInAuthorizedShares
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0677"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:ReclassLiabilityToEquityAfterIncreaseInAuthorizedShares
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0678"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      id="xdx2ixbrl1049"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_country_IL"
      id="xdx2ixbrl1107"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_country_IN"
      id="xdx2ixbrl1109"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_OtherCountryMember"
      id="xdx2ixbrl1112"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2021-12-31_custom_DerivativeLiabilitiesMember"
      id="xdx2ixbrl1167"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_custom_DerivativeLiabilitiesMember"
      id="xdx2ixbrl1171"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2022-12-31_custom_DerivativeLiabilitiesMember"
      id="xdx2ixbrl1175"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_custom_DerivativeLiabilitiesMember"
      id="xdx2ixbrl1179"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2023-12-31_custom_DerivativeLiabilitiesMember"
      id="xdx2ixbrl1183"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1187"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1188"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1192"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1193"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1229"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1230"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1323"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-01-01to2023-12-31" id="Fact000012">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2023-01-01to2023-12-31" id="Fact000013">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000014">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000015">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-12-31" id="Fact000016">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-12-31" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-12-31" id="Fact000018">001-36445</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-12-31" id="Fact000019">NanoVibronix, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-12-31" id="Fact000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-12-31" id="Fact000021">01-0801232</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-12-31" id="Fact000022">969     Pruitt Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-12-31" id="Fact000023">Tyler,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-12-31" id="Fact000024">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-12-31" id="Fact000025">77569</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-12-31" id="Fact000026">(914)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-12-31" id="Fact000027">233-3004</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-01-01to2023-12-31" id="Fact000028">Common     stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-01to2023-12-31" id="Fact000029">NAOV</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-01to2023-12-31" id="Fact000030">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2023-01-01to2023-12-31" id="Fact000031">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2023-01-01to2023-12-31" id="Fact000032">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-12-31" id="Fact000033">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-12-31" id="Fact000034">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-12-31" id="Fact000035">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-12-31" id="Fact000036">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-12-31" id="Fact000037">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2023-01-01to2023-12-31" id="Fact000038">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-01-01to2023-12-31" id="Fact000039">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-12-31" id="Fact000040">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000041"
      unitRef="USD">4830581</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-04-08"
      decimals="INF"
      id="Fact000042"
      unitRef="Shares">2784354</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000043">The
information required by Part III of this Form 10-K, to the extent not set forth herein, is incorporated by reference from the registrant&#x2019;s
definitive proxy statement for its 2024 Annual Meeting of Stockholders. Such proxy statement shall be filed with the Securities and Exchange
Commission within 120 days after the end of the fiscal year to which this report relates</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="From2023-01-01to2023-12-31" id="Fact000044">549</dei:AuditorFirmId>
    <dei:AuditorFirmId contextRef="From2022-01-012022-12-31" id="Fact000045">688</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2023-01-01to2023-12-31" id="Fact000046">Zwick CPA, PLLC</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-01-01to2023-12-31" id="Fact000047">Southfield, Michigan</dei:AuditorLocation>
    <dei:AuditorName contextRef="From2022-01-012022-12-31" id="Fact000048">Marcum LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-01-012022-12-31" id="Fact000049">New York, NY</dei:AuditorLocation>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000057"
      unitRef="USD">3283000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000058"
      unitRef="USD">2713000</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000060"
      unitRef="USD">318000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000061"
      unitRef="USD">9000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000063"
      unitRef="USD">154000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000064"
      unitRef="USD">712000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000066"
      unitRef="USD">2732000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000067"
      unitRef="USD">2175000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000069"
      unitRef="USD">6487000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000070"
      unitRef="USD">5609000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000075"
      unitRef="USD">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000076"
      unitRef="USD">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000078"
      unitRef="USD">1000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000079"
      unitRef="USD">3000</us-gaap:OtherAssetsNoncurrent>
    <NAOV:SeveranceAssetsNoncurent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000081"
      unitRef="USD">174000</NAOV:SeveranceAssetsNoncurent>
    <NAOV:SeveranceAssetsNoncurent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000082"
      unitRef="USD">179000</NAOV:SeveranceAssetsNoncurent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000084"
      unitRef="USD">5000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000085"
      unitRef="USD">81000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000087"
      unitRef="USD">187000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000088"
      unitRef="USD">270000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000090"
      unitRef="USD">6674000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000091"
      unitRef="USD">5879000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000099"
      unitRef="USD">138000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000100"
      unitRef="USD">66000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000102"
      unitRef="USD">2265000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000103"
      unitRef="USD">2148000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000105"
      unitRef="USD">46000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000106"
      unitRef="USD">21000</us-gaap:DeferredRevenue>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000108"
      unitRef="USD">5000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000109"
      unitRef="USD">81000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000111"
      unitRef="USD">2454000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000112"
      unitRef="USD">2316000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000117"
      unitRef="USD">217000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000118"
      unitRef="USD">223000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000120"
      unitRef="USD">15000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000121"
      unitRef="USD">107000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000123"
      unitRef="USD">2686000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000124"
      unitRef="USD">2646000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000135"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000137"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">3000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">3000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000143"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000145"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000147"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000149"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact000154"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact000156"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact000158"
      unitRef="Shares">506</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact000160"
      unitRef="Shares">506</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact000162"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact000164"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact000166"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact000173"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact000175"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact000177"
      unitRef="Shares">1999494</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact000179"
      unitRef="Shares">1999494</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact000181"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact000183"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact000185"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      id="Fact000187"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000192"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000194"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000196"
      unitRef="Shares">40000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000198"
      unitRef="Shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000200"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000202"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000204"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000206"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000214"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000216"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000218"
      unitRef="Shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000220"
      unitRef="Shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000222"
      unitRef="Shares">2046307</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000224"
      unitRef="Shares">2046307</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000226"
      unitRef="Shares">1641146</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000228"
      unitRef="Shares">1641146</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000211"
      unitRef="USD">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000212"
      unitRef="USD">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000230"
      unitRef="USD">70149000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000231"
      unitRef="USD">65634000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000233"
      unitRef="USD">-67000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000234"
      unitRef="USD">-18000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000236"
      unitRef="USD">-66096000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000237"
      unitRef="USD">-62385000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000239"
      unitRef="USD">3988000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000240"
      unitRef="USD">3233000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000242"
      unitRef="USD">6674000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000243"
      unitRef="USD">5879000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000245"
      unitRef="USD">2283000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000246"
      unitRef="USD">752000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000248"
      unitRef="USD">746000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000249"
      unitRef="USD">585000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000251"
      unitRef="USD">1537000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000252"
      unitRef="USD">167000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000257"
      unitRef="USD">185000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000258"
      unitRef="USD">283000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000260"
      unitRef="USD">864000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000261"
      unitRef="USD">965000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000263"
      unitRef="USD">3924000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000264"
      unitRef="USD">3931000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000266"
      unitRef="USD">4973000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000267"
      unitRef="USD">5179000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000269"
      unitRef="USD">-3436000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000270"
      unitRef="USD">-5012000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000272"
      unitRef="USD">135000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000273"
      unitRef="USD">347000</us-gaap:InterestExpense>
    <NAOV:FinancialExpensesNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000275"
      unitRef="USD">-111000</NAOV:FinancialExpensesNet>
    <NAOV:FinancialExpensesNet
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000276"
      unitRef="USD">-54000</NAOV:FinancialExpensesNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000278"
      unitRef="USD">-3682000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000279"
      unitRef="USD">-5413000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000281"
      unitRef="USD">29000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000282"
      unitRef="USD">35000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000284"
      unitRef="USD">-3711000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000285"
      unitRef="USD">-5448000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000287"
      unitRef="USDPShares">-2.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000289"
      unitRef="USDPShares">-2.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000291"
      unitRef="USDPShares">-3.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000293"
      unitRef="USDPShares">-3.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000295"
      unitRef="Shares">1750109</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000297"
      unitRef="Shares">1750109</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000299"
      unitRef="Shares">1419670</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000301"
      unitRef="Shares">1419670</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000306"
      unitRef="USD">-3711000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000307"
      unitRef="USD">-5448000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000309"
      unitRef="USD">49000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000310"
      unitRef="USD">78000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000312"
      unitRef="USD">-3760000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000313"
      unitRef="USD">-5526000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000333"
      unitRef="Shares">1399890</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000319"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000320"
      unitRef="USD">63189000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000321"
      unitRef="USD">60000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000322"
      unitRef="USD">-56937000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact000323"
      unitRef="USD">6313000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000340"
      unitRef="USD">354000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000343"
      unitRef="USD">190000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000355"
      unitRef="USD">310424000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000357"
      unitRef="Shares">240000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000349"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000350"
      unitRef="USD">2089000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000353"
      unitRef="USD">2090000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <NAOV:IssuanceOfRedeemableSharesSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      decimals="-3"
      id="Fact000369"
      unitRef="Shares">27998000</NAOV:IssuanceOfRedeemableSharesSeriesFPreferredStock>
    <NAOV:RedemptionOfRedeemableSharesSeriesFPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      decimals="-3"
      id="Fact000381"
      unitRef="Shares">-27998000</NAOV:RedemptionOfRedeemableSharesSeriesFPreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000393"
      unitRef="Shares">1256</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000388"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000391"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000401"
      unitRef="USD">-78000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000403"
      unitRef="USD">-78000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000412"
      unitRef="USD">-5448000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000413"
      unitRef="USD">-5448000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000433"
      unitRef="Shares">1641146</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000419"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000420"
      unitRef="USD">65634000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000421"
      unitRef="USD">-18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000422"
      unitRef="USD">-62385000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000423"
      unitRef="USD">3233000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000453"
      unitRef="Shares">1641146</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000439"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000440"
      unitRef="USD">65634000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000441"
      unitRef="USD">-18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000442"
      unitRef="USD">-62385000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000443"
      unitRef="USD">3233000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000460"
      unitRef="USD">293000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000463"
      unitRef="USD">293000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000475"
      unitRef="USD">785084000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000477"
      unitRef="Shares">180000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000470"
      unitRef="USD">4215000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000473"
      unitRef="USD">4215000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <NAOV:StockIssuedDuringPeriodSharesPrefundedWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000489"
      unitRef="Shares">203977</NAOV:StockIssuedDuringPeriodSharesPrefundedWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000501"
      unitRef="Shares">5458</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000496"
      unitRef="USD">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000499"
      unitRef="USD">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000513"
      unitRef="Shares">15726</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000521"
      unitRef="USD">-49000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000523"
      unitRef="USD">-49000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000532"
      unitRef="USD">-3711000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000533"
      unitRef="USD">-3711000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000553"
      unitRef="Shares">2046307</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000539"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000540"
      unitRef="USD">70149000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000541"
      unitRef="USD">-67000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000542"
      unitRef="USD">-66096000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000543"
      unitRef="USD">3988000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000573"
      unitRef="Shares">2046307</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000559"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000560"
      unitRef="USD">70149000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000561"
      unitRef="USD">-67000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000562"
      unitRef="USD">-66096000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000563"
      unitRef="USD">3988000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000578"
      unitRef="USD">-3711000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000579"
      unitRef="USD">-5448000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000584"
      unitRef="USD">1000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000585"
      unitRef="USD">1000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000587"
      unitRef="USD">293000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000588"
      unitRef="USD">354000</us-gaap:ShareBasedCompensation>
    <NAOV:NoncashInterestExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000590"
      unitRef="USD">135000</NAOV:NoncashInterestExpense>
    <NAOV:NoncashInterestExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000591"
      unitRef="USD">347000</NAOV:NoncashInterestExpense>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000593"
      unitRef="USD">-2000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000594"
      unitRef="USD">-16000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000599"
      unitRef="USD">309000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000600"
      unitRef="USD">-191000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000602"
      unitRef="USD">-558000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000603"
      unitRef="USD">482000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000605"
      unitRef="USD">557000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000606"
      unitRef="USD">2000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000608"
      unitRef="USD">72000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000609"
      unitRef="USD">-21000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000611"
      unitRef="USD">-18000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000612"
      unitRef="USD">78000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000614"
      unitRef="USD">-67000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000615"
      unitRef="USD">-69000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <NAOV:IncreaseDecreaseInAccruedSeverancePayNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000617"
      unitRef="USD">-1000</NAOV:IncreaseDecreaseInAccruedSeverancePayNet>
    <NAOV:IncreaseDecreaseInAccruedSeverancePayNet
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000618"
      unitRef="USD">-2000</NAOV:IncreaseDecreaseInAccruedSeverancePayNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000620"
      unitRef="USD">-3602000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000621"
      unitRef="USD">-7035000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000626"
      unitRef="USD">1000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000627"
      unitRef="USD">3000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000629"
      unitRef="USD">-1000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000630"
      unitRef="USD">-3000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000635"
      unitRef="USD">4215000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000636"
      unitRef="USD">2090000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000638"
      unitRef="USD">7000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000639"
      unitRef="USD">2000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000641"
      unitRef="USD">4222000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000642"
      unitRef="USD">2092000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000644"
      unitRef="USD">-49000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000645"
      unitRef="USD">-78000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000647"
      unitRef="USD">570000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000648"
      unitRef="USD">-5024000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000650"
      unitRef="USD">2713000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact000651"
      unitRef="USD">7737000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000653"
      unitRef="USD">3283000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000654"
      unitRef="USD">2713000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:NatureOfOperations contextRef="From2023-01-01to2023-12-31" id="Fact000680">&lt;p id="xdx_805_eus-gaap--NatureOfOperations_zJtWRxkiuXu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 - &lt;span id="xdx_828_zCqAWYceMhu1"&gt;DESCRIPTION OF BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NanoVibronix,
Inc. (the &#x201c;Company&#x201d;), a Delaware corporation, commenced operations on October 20, 2003, and is a medical device company focusing
on non-invasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without
the assistance of medical professionals.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s principal research and development activities are conducted in Israel through its wholly-owned subsidiary, NanoVibronix
Ltd., a company registered in Israel, which commenced operations in October 2003.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <NAOV:GoingConcernAndLiquidityTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000682">&lt;p id="xdx_801_ecustom--GoingConcernAndLiquidityTextBlock_zSPRMzuamLj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 - &lt;span&gt;&lt;span id="xdx_821_zXeLx8fPLx6e"&gt;LIQUIDITY AND PLAN OF OPERATIONS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s ability to continue to operate is dependent mainly on its ability to successfully market and sell its products and the
receipt of additional financing until profitability is achieved. In 2023, the Company&#x2019;s cash used in operations was $&lt;span id="xdx_90E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20230101__20231231_zJbtlMUK0BD4" title="Net cash used in operating activities"&gt;3,602,000&lt;/span&gt; and
received net proceeds of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231_zxQxkvHIJr26" title="Proceeds from issuance of common stock"&gt;4,215,000&lt;/span&gt; (net of offering costs of $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230101__20231231_ztn3A15qaxBa" title="Net offering costs"&gt;785,000&lt;/span&gt;) from the sale of our equity securities, leaving a cash balance of
$&lt;span id="xdx_909_eus-gaap--Cash_iI_c20231231__us-gaap--CollateralAxis__custom--SaleOfEquitySecuritiesMember_zJ0SZGau4A08" title="Cash balance"&gt;3,283,000&lt;/span&gt; as of December 31, 2023. Because the Company does not have sufficient resources to fund our operation for the next twelve months
from the date of this filing, management has substantial doubt of the Company&#x2019;s ability to continue as a going concern. The Company
will need to raise additional capital to finance its losses and negative cash flows from operations and may continue to be dependent
on additional capital raising as long as our products do not reach commercial profitability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NAOV:GoingConcernAndLiquidityTextBlock>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000684"
      unitRef="USD">-3602000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000686"
      unitRef="USD">4215000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000688"
      unitRef="USD">785000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31_custom_SaleOfEquitySecuritiesMember"
      decimals="0"
      id="Fact000690"
      unitRef="USD">3283000</us-gaap:Cash>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000692">&lt;p id="xdx_802_eus-gaap--SignificantAccountingPoliciesTextBlock_zMhhuKs0N2i4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 - &lt;span id="xdx_82F_zF3ba3I9cnG5"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z9a5LJKe5Ve9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_863_z2XkwDoFW2fk"&gt;Basis
of presentation and principles of consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements include the accounts of NanoVibronix, Inc. and its wholly owned subsidiary. Intercompany
accounts and transactions have been eliminated. The consolidated financial statements and accompanying notes have been prepared in conformity
with U.S. generally accepted accounting principles (&#x201c;US GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--UseOfEstimates_zrtOcbK35hEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zuPYMrFWIMHa"&gt;Use
of estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available
at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during
the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zj5AecGHAoaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_zjCKA4TA3xIh"&gt;Foreign
currency translation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-U.S.
dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary
balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income,
as appropriate. The cumulative translation losses and gains as of the years ended December 31, 2023 and 2022 were $&lt;span id="xdx_900_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_c20230101__20231231_zxIW2sr4GRBc" title="Gains and losses from foreign currency translation"&gt;49,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_c20220101__20221231_zibSwoKuOXre" title="Gains and losses from foreign currency translation"&gt;85&lt;/span&gt;,000, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zT87UAfv3ITd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zpUfGsNCWLtb"&gt;Earnings
per share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
loss per share was computed using the weighted average number of common shares outstanding. Diluted loss per share includes the effect
of diluted common stock equivalents. Potentially dilutive securities from the exercise of stock option, warrants and exercise of preferred
stock as of December 31, 2023 and 2022, respectively, were excluded from the computation of diluted net loss per share because the effect
of their inclusion would have been antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_zqg0bhgImshk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zMd0YM3oYheg"&gt;Inventory&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course
of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the &#x201c;first-in,
first-out&#x201d; method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
write-offs are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates
the quantities on hand relative to current and historical selling prices and historical and projected sales volume. Based on this evaluation,
provisions are made when required to write-down inventory to its net market value. As of December 31, 2023 and 2022, there was &lt;span id="xdx_90D_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20231231_zscoNThGyBR1" title="Inventory allowance"&gt;&lt;span id="xdx_905_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20221231_zDZBXrAKdGqj" title="Inventory allowance"&gt;no&lt;/span&gt;&lt;/span&gt; allowance
on inventory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zBub7xMBi4ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86E_zALbLjUwiMyi"&gt;Property
and equipment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock_zms75uoM0b79" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the
estimated useful lives of the assets, at the following annual rates:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zVxEgMveUCP6" style="display: none"&gt;SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Computers and peripheral equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zKK0U6Cx9EO9" title="Estimated useful life"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zzBT20EvvuZ2" title="Estimated useful life"&gt;5&lt;/span&gt;-&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zkLGApfTLoE1" title="Estimated useful life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zJ38gLt4VsJl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zutbEPbzgvA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zZ4pbHpF12O7"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of property and equipment may not
be recoverable under the provisions of accounting for the impairment of long-lived assets. If it is determined that an impairment loss
has occurred based upon expected future cash flows, the loss is recognized in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--SequencingPolicyTextBlock_zrcNaqoaar8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zbyTQmiU59Se"&gt;Sequencing&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted a sequencing policy under ASC 815-40-35 whereby if reclassification of contracts from equity to liabilities is necessary
pursuant to ASC 815 due to the Company&#x2019;s inability to demonstrate it has sufficient authorized shares. This was due to the Company
committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized,
certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant
date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment
arrangement are not subject to the sequencing policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--SeverancePayPolicyTextBlock_zi5Wx1PB7XC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zr1jALmLVibk"&gt;Severance
pay&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s liability for severance pay is for its Israeli employees and is calculated pursuant to Israeli Severance Pay Law based
on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large
part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies.
The value of these deposits and policies is recorded as an asset in the Company&#x2019;s balance sheet. Accrued severance pay liability
at December 31, 2023 and 2022 was $&lt;span id="xdx_902_eus-gaap--SeveranceCosts1_c20230101__20231231_znz6mYbLGMY2" title="Severance expenses"&gt;217,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--SeveranceCosts1_c20220101__20221231_zwuzkaAVGI1f" title="Severance expenses"&gt;223&lt;/span&gt;,000, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zTcv7JtqWs0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zjquwFXDYaoa"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its leases in accordance with ASU 2016-02, &#x201c;Leases&#x201d; (Topic 842). This topic requires that a lessee recognize
the assets and liabilities that arise from operating leases. The Company recognizes right-of-use assets and lease liabilities on the
consolidated balance sheet for all leases with a term longer than 12 months and classifies them as operating leases. For leases with a
term of 12 months or less, the Company elects not to recognize lease assets and lease liabilities on those leases.
The right-of-use assets and lease liabilities have been measured by the present value of the Company&#x2019;s remaining lease payments
over the lease term using our incremental borrowing rates or implicit rates, when readily determinable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zbZmu5wX0Wbk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_zpzak3Hz3pDb"&gt;Revenue
recognition&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It
is the Company&#x2019;s policy that revenues from product sales is recognized in accordance with ASC 606 &#x201c;Revenue Recognition.&#x201d;
Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that create(s) enforceable
rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services
to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to
be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance
obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis
of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when
(or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue
recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature
of the Company&#x2019;s revenue recognition and there has been no material effect on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from product sales is recorded at the net sales price, or &#x201c;transaction price,&#x201d; which includes estimates of variable consideration
that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government
rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue.
Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues
from sales to distributors are recognized at the time the products are delivered to the distributors (sell-in&#x201d;). The Company does
not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_z9YHm0YsyFol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_868_zp1He6hhbFt6"&gt;Income
taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d;. This topic prescribes the use of the liability
method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and
tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences
are expected to reverse. The Company provides full valuation allowance, to reduce deferred tax assets to the amount that is more likely
than not to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position
taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than
not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related
appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative
basis) likely to be realized upon ultimate settlement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying consolidated
statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z9pJVmUSzKZe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zHBWsxCasGYh"&gt;Stock-based
compensation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its stock-options awards.
The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and
the expected option term. Expected volatility was calculated based upon similar traded companies&#x2019; historical share price movements.
The expected option term represents the period that the Company&#x2019;s stock options are expected to be outstanding. The Company currently
uses the simplified method and will continue to do so until sufficient historical exercise data supports using expected life assumptions.
The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term. The expected dividend
yield assumption is based on the Company&#x2019;s historical experience and expectation of no future dividend payouts. The Company has
historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z6r11aGklxOc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_z7PJ5nR3gRqe"&gt;Recently
adopted accounting standards&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13,
Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;)
and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, &#x201c;Topic
326&#x201d;). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. This ASU is effective
for interim and annual reporting periods beginning after December 15, 2022. The adoption of Topic 326 did not have a material effect
on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_854_zm3ZCdN7ji0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000694">&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z9a5LJKe5Ve9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_863_z2XkwDoFW2fk"&gt;Basis
of presentation and principles of consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements include the accounts of NanoVibronix, Inc. and its wholly owned subsidiary. Intercompany
accounts and transactions have been eliminated. The consolidated financial statements and accompanying notes have been prepared in conformity
with U.S. generally accepted accounting principles (&#x201c;US GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-12-31" id="Fact000696">&lt;p id="xdx_843_eus-gaap--UseOfEstimates_zrtOcbK35hEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zuPYMrFWIMHa"&gt;Use
of estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available
at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during
the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000698">&lt;p id="xdx_846_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zj5AecGHAoaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_zjCKA4TA3xIh"&gt;Foreign
currency translation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-U.S.
dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary
balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income,
as appropriate. The cumulative translation losses and gains as of the years ended December 31, 2023 and 2022 were $&lt;span id="xdx_900_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_c20230101__20231231_zxIW2sr4GRBc" title="Gains and losses from foreign currency translation"&gt;49,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_c20220101__20221231_zibSwoKuOXre" title="Gains and losses from foreign currency translation"&gt;85&lt;/span&gt;,000, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000700"
      unitRef="USD">49000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000702"
      unitRef="USD">85</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000704">&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zT87UAfv3ITd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zpUfGsNCWLtb"&gt;Earnings
per share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
loss per share was computed using the weighted average number of common shares outstanding. Diluted loss per share includes the effect
of diluted common stock equivalents. Potentially dilutive securities from the exercise of stock option, warrants and exercise of preferred
stock as of December 31, 2023 and 2022, respectively, were excluded from the computation of diluted net loss per share because the effect
of their inclusion would have been antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000706">&lt;p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_zqg0bhgImshk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zMd0YM3oYheg"&gt;Inventory&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course
of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the &#x201c;first-in,
first-out&#x201d; method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
write-offs are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates
the quantities on hand relative to current and historical selling prices and historical and projected sales volume. Based on this evaluation,
provisions are made when required to write-down inventory to its net market value. As of December 31, 2023 and 2022, there was &lt;span id="xdx_90D_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20231231_zscoNThGyBR1" title="Inventory allowance"&gt;&lt;span id="xdx_905_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20221231_zDZBXrAKdGqj" title="Inventory allowance"&gt;no&lt;/span&gt;&lt;/span&gt; allowance
on inventory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryAdjustments
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000708"
      unitRef="USD">0</us-gaap:InventoryAdjustments>
    <us-gaap:InventoryAdjustments
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000710"
      unitRef="USD">0</us-gaap:InventoryAdjustments>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000712">&lt;p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zBub7xMBi4ch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86E_zALbLjUwiMyi"&gt;Property
and equipment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock_zms75uoM0b79" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the
estimated useful lives of the assets, at the following annual rates:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zVxEgMveUCP6" style="display: none"&gt;SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Computers and peripheral equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zKK0U6Cx9EO9" title="Estimated useful life"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zzBT20EvvuZ2" title="Estimated useful life"&gt;5&lt;/span&gt;-&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zkLGApfTLoE1" title="Estimated useful life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zJ38gLt4VsJl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <NAOV:ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000714">&lt;p id="xdx_891_ecustom--ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock_zms75uoM0b79" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the
estimated useful lives of the assets, at the following annual rates:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zVxEgMveUCP6" style="display: none"&gt;SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Computers and peripheral equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zKK0U6Cx9EO9" title="Estimated useful life"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zzBT20EvvuZ2" title="Estimated useful life"&gt;5&lt;/span&gt;-&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zkLGApfTLoE1" title="Estimated useful life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</NAOV:ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember"
      id="Fact000716">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember"
      id="Fact000718">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember"
      id="Fact000720">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000722">&lt;p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zutbEPbzgvA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zZ4pbHpF12O7"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of property and equipment may not
be recoverable under the provisions of accounting for the impairment of long-lived assets. If it is determined that an impairment loss
has occurred based upon expected future cash flows, the loss is recognized in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <NAOV:SequencingPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000724">&lt;p id="xdx_844_ecustom--SequencingPolicyTextBlock_zrcNaqoaar8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zbyTQmiU59Se"&gt;Sequencing&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted a sequencing policy under ASC 815-40-35 whereby if reclassification of contracts from equity to liabilities is necessary
pursuant to ASC 815 due to the Company&#x2019;s inability to demonstrate it has sufficient authorized shares. This was due to the Company
committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized,
certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant
date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment
arrangement are not subject to the sequencing policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NAOV:SequencingPolicyTextBlock>
    <NAOV:SeverancePayPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000726">&lt;p id="xdx_84C_ecustom--SeverancePayPolicyTextBlock_zi5Wx1PB7XC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zr1jALmLVibk"&gt;Severance
pay&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s liability for severance pay is for its Israeli employees and is calculated pursuant to Israeli Severance Pay Law based
on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large
part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies.
The value of these deposits and policies is recorded as an asset in the Company&#x2019;s balance sheet. Accrued severance pay liability
at December 31, 2023 and 2022 was $&lt;span id="xdx_902_eus-gaap--SeveranceCosts1_c20230101__20231231_znz6mYbLGMY2" title="Severance expenses"&gt;217,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--SeveranceCosts1_c20220101__20221231_zwuzkaAVGI1f" title="Severance expenses"&gt;223&lt;/span&gt;,000, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NAOV:SeverancePayPolicyTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000728"
      unitRef="USD">217000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000730"
      unitRef="USD">223</us-gaap:SeveranceCosts1>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000732">&lt;p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zTcv7JtqWs0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zjquwFXDYaoa"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its leases in accordance with ASU 2016-02, &#x201c;Leases&#x201d; (Topic 842). This topic requires that a lessee recognize
the assets and liabilities that arise from operating leases. The Company recognizes right-of-use assets and lease liabilities on the
consolidated balance sheet for all leases with a term longer than 12 months and classifies them as operating leases. For leases with a
term of 12 months or less, the Company elects not to recognize lease assets and lease liabilities on those leases.
The right-of-use assets and lease liabilities have been measured by the present value of the Company&#x2019;s remaining lease payments
over the lease term using our incremental borrowing rates or implicit rates, when readily determinable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000734">&lt;p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zbZmu5wX0Wbk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_zpzak3Hz3pDb"&gt;Revenue
recognition&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;It
is the Company&#x2019;s policy that revenues from product sales is recognized in accordance with ASC 606 &#x201c;Revenue Recognition.&#x201d;
Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that create(s) enforceable
rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services
to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to
be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance
obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis
of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when
(or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue
recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature
of the Company&#x2019;s revenue recognition and there has been no material effect on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from product sales is recorded at the net sales price, or &#x201c;transaction price,&#x201d; which includes estimates of variable consideration
that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government
rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue.
Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues
from sales to distributors are recognized at the time the products are delivered to the distributors (sell-in&#x201d;). The Company does
not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000736">&lt;p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_z9YHm0YsyFol" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_868_zp1He6hhbFt6"&gt;Income
taxes&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d;. This topic prescribes the use of the liability
method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and
tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences
are expected to reverse. The Company provides full valuation allowance, to reduce deferred tax assets to the amount that is more likely
than not to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position
taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than
not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related
appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative
basis) likely to be realized upon ultimate settlement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying consolidated
statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000738">&lt;p id="xdx_844_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z9pJVmUSzKZe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zHBWsxCasGYh"&gt;Stock-based
compensation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its stock-options awards.
The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and
the expected option term. Expected volatility was calculated based upon similar traded companies&#x2019; historical share price movements.
The expected option term represents the period that the Company&#x2019;s stock options are expected to be outstanding. The Company currently
uses the simplified method and will continue to do so until sufficient historical exercise data supports using expected life assumptions.
The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term. The expected dividend
yield assumption is based on the Company&#x2019;s historical experience and expectation of no future dividend payouts. The Company has
historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000740">&lt;p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z6r11aGklxOc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_z7PJ5nR3gRqe"&gt;Recently
adopted accounting standards&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13,
Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;)
and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, &#x201c;Topic
326&#x201d;). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. This ASU is effective
for interim and annual reporting periods beginning after December 15, 2022. The adoption of Topic 326 did not have a material effect
on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000742">&lt;p id="xdx_80B_eus-gaap--OtherCurrentAssetsTextBlock_z6dKrXVSUVy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 - &lt;span id="xdx_82F_zACduIsRXTUl"&gt;PREPAID EXPENSES AND OTHER RECEIVABLES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zml4VAaNeiK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other receivables consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zwUcjli2GCsl" style="display: none"&gt;SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zw4PzUhPFpPj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20221231_zPUCD3xwJU86" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PrepaidExpenseCurrent_iI_maPEAOAzR3N_zuoqKBSmu4G5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;47,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;612,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherAssetsCurrent_iI_maPEAOAzR3N_zStrwIDNGE78" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;107,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0d_mtPEAOAzR3N_zZ16Ro6Mfykk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
    expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;154,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;712,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zQOiAKd4L7gg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000744">&lt;p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zml4VAaNeiK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other receivables consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zwUcjli2GCsl" style="display: none"&gt;SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zw4PzUhPFpPj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20221231_zPUCD3xwJU86" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PrepaidExpenseCurrent_iI_maPEAOAzR3N_zuoqKBSmu4G5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;47,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;612,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherAssetsCurrent_iI_maPEAOAzR3N_zStrwIDNGE78" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;107,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0d_mtPEAOAzR3N_zZ16Ro6Mfykk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
    expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;154,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;712,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000746"
      unitRef="USD">47000000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000747"
      unitRef="USD">612000000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000749"
      unitRef="USD">107000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000750"
      unitRef="USD">100000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000752"
      unitRef="USD">154000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000753"
      unitRef="USD">712000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000755">&lt;p id="xdx_80A_eus-gaap--InventoryDisclosureTextBlock_z7PGaLBKXGa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &#x2013; &lt;span id="xdx_82F_zqi6jWd8qnD7"&gt;INVENTORY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zkWAymJVPFF9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
consists of the following components:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zuVSO2eaDfBc" style="display: none"&gt;SCHEDULE OF INVENTORY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231_zemqrKL0Dkfc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231_zXTg4fLcefL8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--InventoryRawMaterials_iI_maINzmOi_z6PSVDo8sWCa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;210,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;30,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--InventoryFinishedGoods_iI_maINzmOi_zkXLffHVztc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,522,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,145,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InventoryNet_iTI_pp0d_mtINzmOi_zS3z8J2DoyPk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,732,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,175,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zazscUhC5AL" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000757">&lt;p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zkWAymJVPFF9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
consists of the following components:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zuVSO2eaDfBc" style="display: none"&gt;SCHEDULE OF INVENTORY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231_zemqrKL0Dkfc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231_zXTg4fLcefL8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--InventoryRawMaterials_iI_maINzmOi_z6PSVDo8sWCa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;210,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;30,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--InventoryFinishedGoods_iI_maINzmOi_zkXLffHVztc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,522,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,145,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InventoryNet_iTI_pp0d_mtINzmOi_zS3z8J2DoyPk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,732,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,175,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000759"
      unitRef="USD">210000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000760"
      unitRef="USD">30000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000762"
      unitRef="USD">2522000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000763"
      unitRef="USD">2145000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000765"
      unitRef="USD">2732000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000766"
      unitRef="USD">2175000</us-gaap:InventoryNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000768">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zdynC13qUCvk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 - &lt;span id="xdx_820_zMq11RNgCED8"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
common stock confers upon the holders the right to receive notice to participate and vote in general meetings of the Company, and the
right to receive dividends, if declared, and to participate in the distribution of the surplus assets and funds of the Company in the
event of liquidation, dissolution or winding up of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Reverse
stock split&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 8, 2023, the Company effected a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split
shares. The Company&#x2019;s common stock begin trading on a split-adjusted basis when the market opened on February 9, 2023 (the &#x201c;Reverse
Stock Split&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the effective time of the Reverse Stock Split, every 20 shares of the Company&#x2019;s issued and outstanding common stock were converted
automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding
shares through a brokerage account had their shares automatically adjusted to reflect the &lt;span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20230208__20230208_zn9QeyZOk30k" title="Reverse stock split"&gt;1-for-20 Reverse Stock Split&lt;/span&gt;. The Reverse Stock
Split affected all stockholders uniformly and did not alter any stockholder&#x2019;s percentage interest in the Company&#x2019;s equity,
except to the extent that the Reverse Stock Split resulted in a stockholder owning a fractional share. Any fractional share of a stockholder
resulting from the Reverse Stock Split was rounded up to the nearest whole number of shares. Proportional adjustments were made to the
number of shares of the Company&#x2019;s common stock issuable upon exercise or conversion of the Company&#x2019;s equity awards, warrants
and other convertible securities, as well as the applicable exercise or conversion price thereof. On February 16, 2023, the Company rounded
up fractional shares to its nearest whole number of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20230215__20230216_zzzeExuXCVlg" title="Fractional shares"&gt;15,726&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
references in this Report to number of shares, price per share and weighted average number of shares of common stock outstanding prior
to the Reverse Stock Split have been adjusted to reflect the Reverse Stock Split on a retroactive basis, unless otherwise noted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Issuance
of common stock for cash&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
November 29, 2022, the Company entered into a Securities Purchase Agreement with certain institutional investors pursuant to which the
Company agreed to sell in a registered direct offering (the &#x201c;Offering&#x201d;), &lt;span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z7OuHJEMjNv4" title="Sale of stock, number of shares issued"&gt;240,000&lt;/span&gt; shares of the Company&#x2019;s common stock
at an offering price of $&lt;span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zMIkoPsZj1di" title="Sale of stock, price per share"&gt;10.00&lt;/span&gt; per share. The Company received net proceeds from the sale of this offering, after &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;deducting
placement agent fees and expenses and offering expenses payable by the Company, of approximately $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zxeY9O8c3wGe" title="Proceeds from sale of common stock"&gt;2.1&lt;/span&gt; million. &lt;span style="background-color: white"&gt;The
Company intends to use the net proceeds for general working capital purposes.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
October 6, 2022, the Company entered into an engagement letter with H.C. Wainwright &amp;amp; Co., LLC (the &#x201c;Wainwright&#x201d;), pursuant
to which Wainwright agreed to serve as the exclusive placement agent for the Company, on a reasonable best-efforts basis, in connection
with the Offering. The Company will pay Wainwright an aggregate cash fee equal to &lt;span id="xdx_905_ecustom--GrossProceedsOfAggregateCashFeePercentage_pid_dp_c20221005__20221006__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z9QZEZCdPBqf" title="Gross proceeds of aggregate cash fee percentage"&gt;7.5&lt;/span&gt;% of the gross proceeds of the Offering, a management
fee equal to &lt;span id="xdx_903_ecustom--GrossProceedsOfManagementFeePercentage_pid_dp_uPure_c20221005__20221006__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zTSh2YVrJw99" title="Gross proceeds of management fee percentage"&gt;1.0&lt;/span&gt;% of the gross proceeds of the Offering, a non-accountable expense allowance of $&lt;span id="xdx_903_eus-gaap--OtherNoncashExpense_c20221005__20221006__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zbr2yC8O2NYh" title="Non-accountable expense allowance"&gt;50,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ClearanceFees_c20221005__20221006__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zRMTUasLg4j6" title="Clearing fees"&gt;15,950&lt;/span&gt; for clearing fees.
Additionally, the Company has agreed to &lt;span style="background-color: white"&gt;issue&lt;/span&gt; Wainwright or its designees as compensation, warrants to purchase up to &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221006__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zi7ezGVsnek4" title="Warrants issued to purchase common stock"&gt;18,000&lt;/span&gt; shares
of common stock. The warrants expire on &lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221006__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zSc0yXMDba57" title="Warrants expiration date"&gt;November 29, 2027&lt;/span&gt;, and have an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp2d_c20221006__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_z6hcUsn1I6H6" title="Exercise price of warrants per share"&gt;12.50&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Issuance
of common stock for cash through private placement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 30, 2023, the Company entered into a securities purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with an institutional
investor for the issuance and sale in a private placement (the &#x201c;Private Placement&#x201d;) of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN49zSD5n6hd" title="Number of new share issued"&gt;180,000&lt;/span&gt; shares (the &#x201c;Common
Shares&#x201d;) of common stock, par value $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5Ln4jOBWbh" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share (the &#x201c;Common Stock&#x201d;), pre-funded warrants (&#x201c;Pre-Funded Warrants&#x201d;)
to purchase up to &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoAoqAU1UIQi" title="Number of securities called by warrants or rights"&gt;2,726,977&lt;/span&gt; shares of common stock, with an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zloTUA5Uhpg8" title="Class of warrant or right, exercise price of warrants"&gt;0.0001&lt;/span&gt; per share, A-1 Warrants (the &#x201c;A-1 Warrants&#x201d;)
to purchase up to &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zu6F7iJE7Rt8" title="Number of securities called by warrants or rights"&gt;2,906,977&lt;/span&gt; shares of Common Stock, with an exercise price of $&lt;span id="xdx_908_eus-gaap--WarrantExercisePriceIncrease_pid_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zpGACWOnoudd" title="Warrant exercise price"&gt;1.47&lt;/span&gt; per share, and A-2 Warrants (the &#x201c;A-2 Warrants&#x201d;
and together with the A-1 Warrants, the &#x201c;Warrants&lt;b&gt;&lt;i&gt;&#x201d;&lt;/i&gt;&lt;/b&gt; ) to purchase up to &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zli9I0xIz8I5" title="Number of securities called by warrants or rights"&gt;2,906,977&lt;/span&gt; shares of Common Stock with
an exercise price of $&lt;span id="xdx_90D_eus-gaap--WarrantExercisePriceIncrease_pid_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zu9LQknyZXK9" title="Warrant exercise price"&gt;1.47&lt;/span&gt; per share. The A-1 Warrants are exercisable immediately upon issuance and expire &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zKn4VZxG37nd" title="Class of warrant or right expire date"&gt;March 1, 2029&lt;/span&gt;. The A-2 Warrants
are exercisable immediately upon issuance and expire October 1, 2024. The combined purchase price for one Common Share and the accompanying
Warrants was $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_ziSbiBjHpble" title="Class of warrant or right exercise price"&gt;1.72&lt;/span&gt;, and the combined purchase price for one Pre-Funded Warrant and the accompanying Warrants was $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zKmmwAJ9Pn44" title="Shares issued, price per share"&gt;1.7199&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
net proceeds to the Company from the Private Placement are approximately $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230830__20230830__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zmXFUkjXaHXk" title="Proceeds from issuance of private placement"&gt;4,215,000&lt;/span&gt;, after deducting placement agent fees and expenses
and estimated offering expenses payable by the Company. The Company intends to use the net proceeds received from the Private Placement
for general corporate purposes, including funding of our development programs, commercial planning and sales and marketing expenses,
potential strategic acquisitions, general and administrative expenses and working capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;H.C.
Wainwright &amp;amp; Co., LLC (&#x201c;Wainwright&#x201d;) served as the Company&#x2019;s exclusive placement agent in connection with the Private
Placement, pursuant to that certain engagement letter, dated as of July 5, 2023, as amended, between us and Wainwright (the &#x201c;Engagement
Letter&#x201d;). As part of Wainwright&#x2019;s compensation, we issued to Wainwright or its designees warrants (the &#x201c;Placement Agent
Warrants&#x201d;) to purchase up to an aggregate of &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230705__srt--TitleOfIndividualAxis__custom--WainwrightMember_zOEEA3dGoUo" title="Number of securities called by warrants or rights"&gt;218,023&lt;/span&gt; shares of Common Stock at an exercise price equal to $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20230705__srt--TitleOfIndividualAxis__custom--WainwrightMember_zjGWWewN09K9" title="Share price"&gt;2.15&lt;/span&gt; per share. The
Placement Agent Warrants are exercisable immediately upon issuance and expire &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230705__20230705__srt--TitleOfIndividualAxis__custom--WainwrightMember_z51AosqPVYt6" title="Class of warrant or right expire date"&gt;March 1, 2029&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
F Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 13, 2022, the Board declared a dividend of one one-thousandth of a share of Series F Preferred Stock, par value $&lt;span id="xdx_906_eus-gaap--PreferredStockDividendsPerShareDeclared_pid_c20220912__20220913__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_z4U7AXZGeRn4" title="Preferred stock, par value"&gt;0.001&lt;/span&gt; per
share (&#x201c;Series F Preferred Stock&#x201d;), for each one share of the Company&#x2019;s common stock, par value $&lt;span id="xdx_90A_eus-gaap--CommonStockDividendsPerShareDeclared_pid_c20220912__20220913__us-gaap--StatementClassOfStockAxis__custom--SeriesFCommonStockMember_zhr36RNxKgzg" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share, to
stockholders of record at 5:00 p.m. Eastern Time on October 14, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--PreferredStockVotingRights_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zF1xaUVaEejb" title="Preferred stock, voting rights, description"&gt;Each
share of Series F Preferred Stock entitles the holder thereof to 1,000,000 votes per share (and, for the avoidance of doubt, each fraction
of a share of Series F Preferred Stock has a ratable number of votes). Thus, each one-thousandth of a share of Series F Preferred Stock
entitles the holder thereof to 1,000 votes.&lt;/span&gt; The outstanding shares of Series F Preferred Stock will vote together with the outstanding
shares of common stock of the Company as a single class exclusively with respect to (1) any proposal to adopt an amendment to Certificate
of Incorporation to reclassify the outstanding shares of common stock at a ratio specified in or determined in accordance with the terms
of such amendment (the &#x201c;Reverse Stock Split&#x201d;) and (2) any proposal to adjourn any meeting of stockholders called for the
purpose of voting on the Reverse Stock Split (the &#x201c;Adjournment Proposal&#x201d;). The Series F Preferred Stock is not entitled to
vote on any other matter, except to the extent required under the Delaware General Corporation Law.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unless
otherwise provided on any applicable proxy or ballot with respect to the voting on the Reverse Stock Split or the Adjournment Proposal,
the vote of each share of Series F Preferred Stock (or fraction thereof) entitled to vote on the Reverse Stock Split, the Adjournment
Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal
will be cast in the same manner as the vote, if any, of the share of common stock (or fraction thereof) in respect of which such share
of Series F Preferred Stock (or fraction thereof) was issued as a dividend is cast on the Reverse Stock Split, the Adjournment Proposal
or such other matter, as applicable, and the proxy or ballot with respect to shares of common stock held by any holder on whose behalf
such proxy or ballot is submitted will be deemed to include all shares of Series F Preferred Stock (or fraction thereof) held by such
holder. Holders of Series F Preferred Stock will not receive a separate ballot or proxy to cast votes with respect to the Series F Preferred
Stock on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote
on the Reverse Stock Split. All shares of Series F Preferred Stock that are not present in person or by proxy at any meeting of stockholders
held to vote on the Reverse Stock Split and the Adjournment Proposal as of immediately prior to the opening of the polls at such meeting
(the &#x201c;Initial Redemption Time&#x201d;) will automatically be redeemed in whole, but not in part, by the Company at the Initial Redemption
Time without further action on the part of the Company or the holder of shares of Series F Preferred Stock (the &#x201c;Initial Redemption&#x201d;).
Any outstanding shares of Series F Preferred Stock that have not been redeemed pursuant to an Initial Redemption will be redeemed in
whole, but not in part, (i) if such redemption is ordered by the Board in its sole discretion, automatically and effective on such time
and date specified by the Board in its sole discretion or (ii) automatically upon the approval by the Company&#x2019;s stockholders of
the Reverse Stock Split at any meeting of the stockholders held for the purpose of voting on such proposal (the &#x201c;Subsequent Redemption&#x201d;
and, together with the Initial Redemption, the &#x201c;Redemption&#x201d;). As of December 31, 2023, both the Initial Redemption and the
Subsequent Redemption have occurred. As a result, no shares of Series F Preferred Stock remain outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
share of Series F Preferred Stock redeemed in any redemption described above will be redeemed in consideration for the right to receive
an amount equal to $&lt;span id="xdx_90D_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zJqurAub1Xw9" title="Preferred stock, redemption price per share"&gt;0.10&lt;/span&gt; in cash for each one hundred whole shares of Series F Preferred Stock that are &#x201c;beneficially owned&#x201d;
by the &#x201c;beneficial owner&#x201d; (as such terms are defined in the Certificate of Designation) thereof as of the applicable redemption
time and redeemed pursuant to such redemption, payable upon receipt by the Company of a written request submitted by the applicable holder
to the corporate secretary of the Company (each a &#x201c;Redemption Payment Request&#x201d;) following the applicable redemption time.
Such Redemption Payment Request shall (i) be in a form reasonably acceptable to the Company (ii) set forth in reasonable detail the number
of shares of Series F Preferred Stock beneficially owned by the holder at the applicable redemption time and include evidence reasonably
satisfactory to the Company regarding the same, and (iii) set forth a calculation specifying the amount in cash owed to such Holder by
the Company with respect to the shares of Series F Preferred Stock that were redeemed at the applicable redemption time. However, the
redemption consideration in respect of the shares of Series F Preferred Stock (or fractions thereof) redeemed in any redemption described
above: (i) will entitle the former beneficial owners of less than one hundred whole shares of Series F Preferred Stock redeemed in any
redemption to no cash payment in respect thereof and (y) will, in the case of a former beneficial owner of a number of shares of Series
F Preferred Stock (or fractions thereof) redeemed pursuant to any redemption that is not equal to a whole number that is a multiple of
one hundred, entitle such beneficial owner to the same cash payment, if any, in respect of such redemption as would have been payable
in such redemption to such beneficial owner if the number of shares (or fractions thereof) beneficially owned by such beneficial owner
and redeemed pursuant to such redemption were rounded down to the nearest whole number that is a multiple of one hundred (such, that
for example, the former beneficial owner of 150 shares of Series F Preferred Stock redeemed pursuant to any redemption will be entitled
to receive the same cash payment in respect of such redemption as would have been payable to the former beneficial owner of 100 shares
of Series F Preferred Stock redeemed pursuant to such redemption).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No
shares of Series F Preferred Stock may be transferred by the holder thereof except in connection with a transfer by such holder of any
shares of common stock held by such holder, in which case a number of one one-thousandths (1/1,000ths) of a share of Series F Preferred
Stock equal to the number of shares of common stock to be transferred by such holder will be automatically transferred to the transferee
of such shares of common stock. The holders of Series F Preferred Stock, as such, are not entitled to receive dividends of any kind.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Certificate of Designation was filed with the Delaware Secretary of State and became effective on September 14, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
described in the proxy statement filed on October 31, 2022, holders of The Company&#x2019;s common stock and Series F Preferred Stock
as of the close of business on October 17, 2022, are entitled to vote on the amendment to the Company&#x2019;s Certificate of Incorporation
to effect, at the discretion of the Company&#x2019;s Board but prior to the six-month anniversary of the date on which the reverse stock
split is approved by the Company&#x2019;s stockholders at the Annual Meeting, a reverse stock split of all of the outstanding shares of
the Company&#x2019;s common stock at a ratio in the range of 1-for-2 to 1-for-50, with such ratio to be determined by the Board in its
discretion and included in a public announcement, and the proposal to adjourn the Annual Meeting to a later date at the Annual Meeting
held on December 15, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;i&gt;Stock-based
compensation and options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 28, 2014, stockholders approved the NanoVibronix, Inc. 2014 Long-Term Incentive Plan (the &#x201c;2014 Plan&#x201d;), which was
adopted by the Board on February 19, 2014. As of December 31, 2022, under the 2014 Plan, &lt;span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20221231__us-gaap--AwardTypeAxis__custom--TwoThousandFourteenLongTermIncentivePlanMember_zJTvtqg9baJ1" title="Stock reserved for future issuance"&gt;4,864,286&lt;/span&gt; shares of our common stock were reserved
for issuance. On February 9, 2023, the Company effected a &lt;span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20230209__20230209__us-gaap--AwardTypeAxis__custom--TwoThousandFourteenLongTermIncentivePlanMember_z8pwzaAvQUo1" title="Reverse stock split"&gt;one-for-twenty reverse stock split&lt;/span&gt; of common stock. Consequently, the number
of shares of common stock of the Company reserved for issuance pursuant to awards under the 2014 Plan was reduced to &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_c20230209__20230209__us-gaap--AwardTypeAxis__custom--TwoThousandFourteenLongTermIncentivePlanMember_zvf5eMbeIYSl" title="Reduction in stock reserved for future issuance"&gt;243,214&lt;/span&gt; shares.
As of December 31, 2023, there were &lt;span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231__us-gaap--AwardTypeAxis__custom--TwoThousandFourteenLongTermIncentivePlanMember_zRnd970hDnz8" title="Stock reserved for future issuance"&gt;130,529&lt;/span&gt; shares of common stock available to be issued under the plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2023 and 2022, &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zqL3LA1mYUxk" title="Number of options, exercised"&gt;5,459&lt;/span&gt;
and &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zanA3wyli7Gk" title="Number of options, exercised"&gt;1,256&lt;/span&gt;
employee options were exercised, &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zCHyeGFC3cL" title="Number of employee options granted"&gt;80,000&lt;/span&gt;
and &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_ziOyf9N0uTq5" title="Number of employee options granted"&gt;21,875&lt;/span&gt;
options were granted, &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zhm7FRql3JU6" title="Number of employee options forfeited"&gt;105,425&lt;/span&gt;
and &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zeuJQUgcm4mb" title="Number of employee options forfeited"&gt;0&lt;/span&gt;
options were forfeited and &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zlyPGWbJeNWc" title="Number of employee options expired"&gt;4,050&lt;/span&gt;
and &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zSMicKH5YgLc" title="Number of employee options expired"&gt;0&lt;/span&gt;
options were expired, respectively. The options granted during 2023 and 2022 vest at different schedules ranging from date granted
to &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zwfRhQsGxaa3" title="Fair value options vesting term"&gt;9&lt;/span&gt;
years and were recorded at fair values of approximately $&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zlOZdCcVzEL8" title="Number of options, vested"&gt;87,000&lt;/span&gt;
and $&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z04DoXqX8Oij" title="Number of options, vested"&gt;201,000&lt;/span&gt;,
respectively. The maximum contractual term for granted options is &lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod_dtY_c20230101__20231231_zcF7SJ14JCLf" title="Contractual term for granted options"&gt;10&lt;/span&gt; years. During the years ended December 31, 2023 and 2022,
stock-based compensation expense of approximately $&lt;span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z6PrcObaNAz1" title="Stock-based compensation expense"&gt;292,000&lt;/span&gt;
and $&lt;span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zf625EyNiuYi" title="Stock-based compensation expense"&gt;148,000&lt;/span&gt;
was recorded for options that vested, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zLlKv9UH6Az7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zdfQKWvASG05" style="display: none"&gt;SCHEDULE OF OPTIONS ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Shares Under&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zJnmDLoIdWbc" style="width: 14%; text-align: right" title="Options, Outstanding - Beginning balance"&gt;147,619&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zao1hVbtQrmc" style="width: 14%; text-align: right" title="Weighted Average Exercise Price per Share, Exercisable - Ending balance"&gt;24.42&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zpucLGEcuBFi" title="Weighted Average Remaining Life (Years), Outstanding"&gt;7.24&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zKMPDcRi2ds1" style="text-align: right" title="Options, Granted"&gt;80,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z7zZBJ4nUBN" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;1.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zYgoznKT1tY1" title="Weighted Average Remaining Life (Years), Granted"&gt;9.89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zrqeBucxaij9" style="text-align: right" title="Options, Forfeited"&gt;(105,425&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z49RN00wYx57" style="text-align: right" title="Weighted Average Exercise Price per Share, Forfeited"&gt;19.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zJOmzBCt0f1k" title="Weighted Average Remaining Life (Years), Forfeited"&gt;7.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zKkooCdSg0l" style="text-align: right" title="Options, Expired"&gt;(4,050&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zlbmBHM64Yg7" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;34.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zX9m31bWRxUf" title="Weighted Average Remaining Life (Years), Expired"&gt;1.31&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zRkFxqDoETZa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Exercised"&gt;(5,459&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zYZjBWUQ9FR6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;1.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zTxL9pWVr8ij" title="Weighted Average Remaining Life (Years), Exercised"&gt;0.76&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding &#x2013; December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zq1JJtuaVGCh" style="text-align: right" title="Options, Outstanding - Ending balance"&gt;112,685&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zFSnT4A1a6Ma" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding - ending balance"&gt;13.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zxpJHh8Uv8D4" title="Weighted Average Remaining Life (Years), Outstanding"&gt;8.41&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable &#x2013; December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Outstanding - Ending balance"&gt;&lt;p id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zb5S7WPl94fi" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Options, Exercisable - Ending balance"&gt;108,691&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding - ending balance"&gt;&lt;p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zeQVoOYu7LN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Weighted Average Exercise Price per Share, Outstanding - ending balance"&gt;12.90&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zmSQ55gWwLVd" title="Weighted Average Remaining Life (Years), Exercisable"&gt;8.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zRHdhkNqFuMe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The outstanding
options had &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20231231_zpWbHyVYXiei" title="Aggregate intrinsic value"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_do_c20221231_zwd4b0PhAV0f" title="Aggregate intrinsic value"&gt;no&lt;/span&gt;&lt;/span&gt; aggregate intrinsic value as of December 31, 2023 and 2022. The intrinsic value is calculated as the difference between
the exercise price and the market value of the shares on the balance sheet date. The market values based on the closing bid price as of
December 31, 2023 and 2022 was $&lt;span id="xdx_905_eus-gaap--SharePrice_iI_c20231231_zojIPmN8pE4a" title="Bid price"&gt;1.15&lt;/span&gt;&#160;and $&lt;span id="xdx_909_eus-gaap--SharePrice_iI_c20221231_zG67IVwrndO9" title="Bid price"&gt;5.04&lt;/span&gt;, respectively.&#160; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zfO15cNCQ2p5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value for options granted in 2023 and 2022 is estimated at the date of grant using a Black-Scholes-Merton options pricing model
with the following underlying assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zJqXsND197q3" style="display: none"&gt;SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Price at valuation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MinimumMember_zD5AMhBHqdx3" title="Price at valuation"&gt;1.20&lt;/span&gt; &#x2013; &lt;span id="xdx_905_eus-gaap--SharePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MaximumMember_zuGAEx4pHPp3" title="Price at valuation"&gt;1.24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--SharePrice_iI_pp2d_c20221231__srt--RangeAxis__srt--MinimumMember_zfjbZlPDR13l" title="Price at valuation"&gt;0.45&lt;/span&gt; &#x2013; &lt;span id="xdx_90D_eus-gaap--SharePrice_iI_pp2d_c20221231__srt--RangeAxis__srt--MaximumMember_zVkBxu5Bwks5" title="Price at valuation"&gt;0.78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MinimumMember_zgCxg6vIQmn3" title="Exercise price"&gt;1.20&lt;/span&gt; &#x2013; &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MaximumMember_zD5wAFjsrb0c" title="Exercise price"&gt;1.24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20221231__srt--RangeAxis__srt--MinimumMember_zaRNpwmv3aYi" title="Exercise price"&gt;0.45&lt;/span&gt; &#x2013; &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20221231__srt--RangeAxis__srt--MaximumMember_zacpxY0AecZa" title="Exercise price"&gt;0.78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zQiU1OA1QHB9" title="Risk free interest, minimum"&gt;3.83&lt;/span&gt; &#x2013; &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230101__20231231_za24oKGlCfC8" title="Risk free interest, maximum"&gt;4.42&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231_zXUZ9yXFob0d" title="Risk free interest, minimum"&gt;2.32&lt;/span&gt; &#x2013; &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20220101__20221231_zcxUlKjlsR11" title="Risk free interest, maximum"&gt;3.58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zhSPccQc8dVf" title="Expected term (in years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zS4NoJ9bUba1" title="Expected term (in years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_zP1aysdxDoG4" title="Volatility, minimum"&gt;133.1&lt;/span&gt; &#x2013; &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zzT87pzCPLhe" title="Volatility, maximum"&gt;133.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220101__20221231_zTlYW2vnEVx9" title="Volatility, minimum"&gt;125.3&lt;/span&gt; &#x2013; &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220101__20221231_zMBuzVpwVAw9" title="Volatility, maximum"&gt;127.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_znQfi2TzMKDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zaHcaYHmaBOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the
following table.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zWVm1EW9sx5a" style="display: none"&gt;SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zPHTUfWKVGv5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20221231_zj8rGqHETkD6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zDSJmr7xVtl8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_z8t61S4MTrn6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Selling and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zkeC21OcHEN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;258,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;323,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zLZg7zNi2ph6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;292,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;354,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zzYW8bSwWdn8" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Stock based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;292,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;354,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AD_zUYFVNWtbjUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that
date was approximately $&lt;span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20231231_zj2inrgSYQac" title="Non-vested stock options granted, unrecognized estimated compensation cost"&gt;123,000&lt;/span&gt;,
which is expected to be recognized over a weighted average period of approximately &lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231_z5uGDf0ckrX7" title="Non-vested stock options granted, weighted average period"&gt;0.97&lt;/span&gt;
years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
June 14, 2022, the Company issued warrants to two sales consultants to purchase &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220614_zkZZHBSLMDAi" title="Purchase of warrants"&gt;12,500&lt;/span&gt; shares of common stock which will expire on &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220614_zu0ES4gYBU46" title="Warrants expire date"&gt;June
14, 2029&lt;/span&gt; and have an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220614_zEsfaRGBKgH3" title="Warrants exercise price"&gt;20.00&lt;/span&gt; per share. Accordingly, expense related to these warrants in the amount of $&lt;span id="xdx_907_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_pn3n3_c20220613__20220614_zuRWEamoCSY7" title="Increase in additional paid in capital warrants"&gt;135,000&lt;/span&gt; was
recorded with a corresponding increase in additional paid in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 30, 2022, the Company and the two sales consultants mutually agreed to cancel the latter&#x2019;s annual stock warrants to purchase
&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220930_zfGGPtcuhf7d" title="Purchase of warrants"&gt;12,500&lt;/span&gt; shares of common stock. Accordingly, expense related to these warrants were reversed in the amount of $&lt;span id="xdx_90D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c20220929__20220930_zgZS4RW63uG3" title="Increase in additional paid in capital warrants"&gt;135,000&lt;/span&gt; with a corresponding
decrease in additional paid in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 29, 2022, the Company granted &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221129_zss4AzdCj5Z4" title="Number of warrants to purchase"&gt;18,000&lt;/span&gt; warrants to purchase Company&#x2019;s common stock in conjunction with the private placements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 30, 2023, the Company granted (a) Pre-Funded Warrants to purchase up to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMdOIset5sYj" title="Warrants issued to purchase common stock"&gt;2,906,977&lt;/span&gt; shares of Common Stock with an exercise price
of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWMBwM5emKEh" title="Class of warrant or right exercise price"&gt;0.0001&lt;/span&gt; per share, (b) A-1 Warrants to purchase up to &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_ztfsnhWBh1ve" title="Warrants issued to purchase common stock"&gt;2,906,977&lt;/span&gt; shares of Common Stock with an exercise price of $&lt;span id="xdx_906_eus-gaap--WarrantExercisePriceIncrease_pid_c20230830__20230830__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zZ77AF0lCYhd" title="Warrant exercise price"&gt;1.47&lt;/span&gt; per share and
(c) A-2 Warrants to purchase up to &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zXN4SscjRVK6" title="Warrants issued to purchase common stock"&gt;2,906,977&lt;/span&gt; shares of Common Stock with an exercise price of $&lt;span id="xdx_90E_eus-gaap--WarrantExercisePriceIncrease_pid_c20230830__20230830__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zSGuXl5hDjKh" title="Warrant exercise price"&gt;1.47&lt;/span&gt; per share, or a total of &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230830__20230830__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zvxp0WeDMV3j" title="Number of new share issued"&gt;8,540,931&lt;/span&gt;
warrants, in conjunction with the Private Placement disclosed above. The A-1 Warrants and A-2 Warrants are exercisable immediately upon
issuance and expire on &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zn20lldpPef4" title="Class of warrant or right expire date"&gt;March 1, 2029&lt;/span&gt; and &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zJSgeM8bsA7d" title="Class of warrant or right expire date"&gt;October 1, 2024&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the same Private Placement, the Company granted Placement Agent Warrants to Wainwright, or its designees, to purchase up to an aggregate
of &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__srt--TitleOfIndividualAxis__custom--WainwrightMember_zC0SpJtS4Smj" title="Warrants issued to purchase common stock"&gt;218,023&lt;/span&gt; shares of Common Stock at an exercise price equal to $&lt;span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20230830__srt--TitleOfIndividualAxis__custom--WainwrightMember_zGK7mEgdgKhh" title="Share price"&gt;2.15&lt;/span&gt; per share. The Placement Agent Warrants are exercisable immediately
upon issuance and expire &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__srt--TitleOfIndividualAxis__custom--WainwrightMember_z6h8gdKE6ye9" title="Class of warrant or right expire date"&gt;March 1, 2029&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock_z4WHOPXwO2u7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
estimating the warrants&#x2019; fair value, the Company used the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zntZVCIjzloj" style="display: none"&gt;SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Risk free interest&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zPSM0kkdCU8a" title="Warrants, measurement input, percentage"&gt;3.49&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zc4BFqlvwVNe" title="Warrants, measurement input, percentage"&gt;0.34&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z3rSXmAGrMHe" title="Warrants, measurement input, percentage"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zh61Njy3Jt93" title="Warrants, measurement input, percentage"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zEqt4fmmmtgf" title="Warrants, measurement input, percentage"&gt;147.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zyCq4Saf5nFk" title="Warrants, measurement input, percentage"&gt;60.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Contractual term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231_zMtzR3hQAEy1" title="Contractual term (in years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231_zCrINF3wfYR1" title="Contractual term (in years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z07HCMweJ6Ng" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z9Vp5YaeRglb" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zGwujhMpJKVe"&gt;SCHEDULE OF WARRANTS ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zKTBmul4B60j" style="width: 16%; text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;115,467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zsxWxXAhOpwj" style="text-align: right" title="Warrants, Granted"&gt;30,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zfs3ECAcZDl3" style="text-align: right" title="Warrants, Expired"&gt;(55,215&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zcICGpmD13mi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Canceled"&gt;(12,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z7OIxMkvly3b" style="text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;78,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z5iZiciNXeCd" style="text-align: right" title="Warrants, Granted"&gt;8,758,954&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zpWtZzayOS8h" style="text-align: right" title="Warrants, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1049"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z1Y991JR6Mc3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Canceled"&gt;(203,977&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding &#x2013; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zRiHkVV0GT9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding - Ending balance"&gt;8,633,229&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zKcTY0nctnVf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2023-02-082023-02-08" id="Fact000770">1-for-20 Reverse Stock Split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2023-02-152023-02-16"
      decimals="INF"
      id="Fact000772"
      unitRef="Shares">15726</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-11-282022-11-29_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000774"
      unitRef="Shares">240000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-11-29_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000776"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-11-282022-11-29_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact000778"
      unitRef="USD">2100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <NAOV:GrossProceedsOfAggregateCashFeePercentage
      contextRef="From2022-10-052022-10-06_custom_HCWainwrightAndCoLLCMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000780"
      unitRef="Pure">0.075</NAOV:GrossProceedsOfAggregateCashFeePercentage>
    <NAOV:GrossProceedsOfManagementFeePercentage
      contextRef="From2022-10-052022-10-06_custom_HCWainwrightAndCoLLCMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000782"
      unitRef="Pure">0.010</NAOV:GrossProceedsOfManagementFeePercentage>
    <us-gaap:OtherNoncashExpense
      contextRef="From2022-10-052022-10-06_custom_HCWainwrightAndCoLLCMember"
      decimals="0"
      id="Fact000784"
      unitRef="USD">50000</us-gaap:OtherNoncashExpense>
    <us-gaap:ClearanceFees
      contextRef="From2022-10-052022-10-06_custom_HCWainwrightAndCoLLCMember"
      decimals="0"
      id="Fact000786"
      unitRef="USD">15950</us-gaap:ClearanceFees>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-10-06_custom_HCWainwrightAndCoLLCMember"
      decimals="INF"
      id="Fact000788"
      unitRef="Shares">18000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2022-10-06_custom_HCWainwrightAndCoLLCMember"
      id="Fact000790">2027-11-29</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-10-06_custom_HCWainwrightAndCoLLCMember"
      decimals="2"
      id="Fact000792"
      unitRef="USDPShares">12.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000794"
      unitRef="Shares">180000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000796"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000798"
      unitRef="Shares">2726977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000800"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember"
      decimals="INF"
      id="Fact000802"
      unitRef="Shares">2906977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember"
      decimals="INF"
      id="Fact000804"
      unitRef="USDPShares">1.47</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember"
      decimals="INF"
      id="Fact000806"
      unitRef="Shares">2906977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember"
      decimals="INF"
      id="Fact000808"
      unitRef="USDPShares">1.47</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember"
      id="Fact000810">2029-03-01</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember"
      decimals="INF"
      id="Fact000812"
      unitRef="USDPShares">1.72</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember"
      decimals="INF"
      id="Fact000814"
      unitRef="USDPShares">1.7199</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-08-302023-08-30_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact000816"
      unitRef="USD">4215000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-05_custom_WainwrightMember"
      decimals="INF"
      id="Fact000818"
      unitRef="Shares">218023</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="AsOf2023-07-05_custom_WainwrightMember"
      decimals="INF"
      id="Fact000820"
      unitRef="USDPShares">2.15</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="From2023-07-052023-07-05_custom_WainwrightMember"
      id="Fact000822">2029-03-01</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="From2022-09-122022-09-13_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000824"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="From2022-09-122022-09-13_custom_SeriesFCommonStockMember"
      decimals="INF"
      id="Fact000826"
      unitRef="USDPShares">0.001</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockVotingRights
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesFPreferredStockMember"
      id="Fact000828">Each
share of Series F Preferred Stock entitles the holder thereof to 1,000,000 votes per share (and, for the avoidance of doubt, each fraction
of a share of Series F Preferred Stock has a ratable number of votes). Thus, each one-thousandth of a share of Series F Preferred Stock
entitles the holder thereof to 1,000 votes.</us-gaap:PreferredStockVotingRights>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      id="Fact000830"
      unitRef="USDPShares">0.10</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-12-31_custom_TwoThousandFourteenLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact000832"
      unitRef="Shares">4864286</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2023-02-092023-02-09_custom_TwoThousandFourteenLongTermIncentivePlanMember"
      id="Fact000834">one-for-twenty reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="From2023-02-092023-02-09_custom_TwoThousandFourteenLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact000836"
      unitRef="Shares">243214</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31_custom_TwoThousandFourteenLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact000838"
      unitRef="Shares">130529</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000840"
      unitRef="Shares">5459</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000842"
      unitRef="Shares">1256</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000844"
      unitRef="Shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000846"
      unitRef="Shares">21875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000848"
      unitRef="Shares">105425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000850"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000852"
      unitRef="Shares">4050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-01-012022-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000854"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      id="Fact000856">P9Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="0"
      id="Fact000858"
      unitRef="USD">87000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2022-01-012022-12-31_custom_EmployeeOptionsMember"
      decimals="0"
      id="Fact000860"
      unitRef="USD">201000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <NAOV:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod contextRef="From2023-01-01to2023-12-31" id="Fact000862">P10Y</NAOV:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="0"
      id="Fact000864"
      unitRef="USD">292000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_custom_EmployeeOptionsMember"
      decimals="0"
      id="Fact000866"
      unitRef="USD">148000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000868">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zLlKv9UH6Az7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zdfQKWvASG05" style="display: none"&gt;SCHEDULE OF OPTIONS ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Shares Under&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%"&gt;Outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zJnmDLoIdWbc" style="width: 14%; text-align: right" title="Options, Outstanding - Beginning balance"&gt;147,619&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zao1hVbtQrmc" style="width: 14%; text-align: right" title="Weighted Average Exercise Price per Share, Exercisable - Ending balance"&gt;24.42&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zpucLGEcuBFi" title="Weighted Average Remaining Life (Years), Outstanding"&gt;7.24&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zKMPDcRi2ds1" style="text-align: right" title="Options, Granted"&gt;80,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z7zZBJ4nUBN" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;1.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zYgoznKT1tY1" title="Weighted Average Remaining Life (Years), Granted"&gt;9.89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zrqeBucxaij9" style="text-align: right" title="Options, Forfeited"&gt;(105,425&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z49RN00wYx57" style="text-align: right" title="Weighted Average Exercise Price per Share, Forfeited"&gt;19.76&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zJOmzBCt0f1k" title="Weighted Average Remaining Life (Years), Forfeited"&gt;7.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zKkooCdSg0l" style="text-align: right" title="Options, Expired"&gt;(4,050&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zlbmBHM64Yg7" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;34.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zX9m31bWRxUf" title="Weighted Average Remaining Life (Years), Expired"&gt;1.31&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zRkFxqDoETZa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Exercised"&gt;(5,459&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zYZjBWUQ9FR6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;1.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zTxL9pWVr8ij" title="Weighted Average Remaining Life (Years), Exercised"&gt;0.76&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding &#x2013; December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zq1JJtuaVGCh" style="text-align: right" title="Options, Outstanding - Ending balance"&gt;112,685&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zFSnT4A1a6Ma" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding - ending balance"&gt;13.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zxpJHh8Uv8D4" title="Weighted Average Remaining Life (Years), Outstanding"&gt;8.41&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable &#x2013; December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Outstanding - Ending balance"&gt;&lt;p id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zb5S7WPl94fi" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Options, Exercisable - Ending balance"&gt;108,691&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding - ending balance"&gt;&lt;p id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zeQVoOYu7LN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Weighted Average Exercise Price per Share, Outstanding - ending balance"&gt;12.90&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zmSQ55gWwLVd" title="Weighted Average Remaining Life (Years), Exercisable"&gt;8.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000870"
      unitRef="Shares">147619</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeeOptionsMember"
      decimals="2"
      id="Fact000872"
      unitRef="USDPShares">24.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      id="Fact000874">P7Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000876"
      unitRef="Shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="2"
      id="Fact000878"
      unitRef="USDPShares">1.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      id="Fact000880">P9Y10M20D</NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000882"
      unitRef="Shares">105425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="2"
      id="Fact000884"
      unitRef="USDPShares">19.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      id="Fact000886">P7Y2M26D</NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000888"
      unitRef="Shares">4050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="2"
      id="Fact000890"
      unitRef="USDPShares">34.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      id="Fact000892">P1Y3M21D</NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000894"
      unitRef="Shares">5459</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      decimals="2"
      id="Fact000896"
      unitRef="USDPShares">1.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      id="Fact000898">P0Y9M3D</NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000900"
      unitRef="Shares">112685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_EmployeeOptionsMember"
      decimals="2"
      id="Fact000902"
      unitRef="USDPShares">13.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      id="Fact000904">P8Y4M28D</NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000906"
      unitRef="Shares">108691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      id="Fact000908"
      unitRef="USDPShares">12.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_custom_EmployeeOptionsMember"
      id="Fact000910">P8Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000912"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000914"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000916"
      unitRef="USDPShares">1.15</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000918"
      unitRef="USDPShares">5.04</us-gaap:SharePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000920">&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zfO15cNCQ2p5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value for options granted in 2023 and 2022 is estimated at the date of grant using a Black-Scholes-Merton options pricing model
with the following underlying assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zJqXsND197q3" style="display: none"&gt;SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Price at valuation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MinimumMember_zD5AMhBHqdx3" title="Price at valuation"&gt;1.20&lt;/span&gt; &#x2013; &lt;span id="xdx_905_eus-gaap--SharePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MaximumMember_zuGAEx4pHPp3" title="Price at valuation"&gt;1.24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--SharePrice_iI_pp2d_c20221231__srt--RangeAxis__srt--MinimumMember_zfjbZlPDR13l" title="Price at valuation"&gt;0.45&lt;/span&gt; &#x2013; &lt;span id="xdx_90D_eus-gaap--SharePrice_iI_pp2d_c20221231__srt--RangeAxis__srt--MaximumMember_zVkBxu5Bwks5" title="Price at valuation"&gt;0.78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MinimumMember_zgCxg6vIQmn3" title="Exercise price"&gt;1.20&lt;/span&gt; &#x2013; &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20231231__srt--RangeAxis__srt--MaximumMember_zD5wAFjsrb0c" title="Exercise price"&gt;1.24&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20221231__srt--RangeAxis__srt--MinimumMember_zaRNpwmv3aYi" title="Exercise price"&gt;0.45&lt;/span&gt; &#x2013; &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20221231__srt--RangeAxis__srt--MaximumMember_zacpxY0AecZa" title="Exercise price"&gt;0.78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zQiU1OA1QHB9" title="Risk free interest, minimum"&gt;3.83&lt;/span&gt; &#x2013; &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20230101__20231231_za24oKGlCfC8" title="Risk free interest, maximum"&gt;4.42&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231_zXUZ9yXFob0d" title="Risk free interest, minimum"&gt;2.32&lt;/span&gt; &#x2013; &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20220101__20221231_zcxUlKjlsR11" title="Risk free interest, maximum"&gt;3.58&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zhSPccQc8dVf" title="Expected term (in years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zS4NoJ9bUba1" title="Expected term (in years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_zP1aysdxDoG4" title="Volatility, minimum"&gt;133.1&lt;/span&gt; &#x2013; &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zzT87pzCPLhe" title="Volatility, maximum"&gt;133.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220101__20221231_zTlYW2vnEVx9" title="Volatility, minimum"&gt;125.3&lt;/span&gt; &#x2013; &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220101__20221231_zMBuzVpwVAw9" title="Volatility, maximum"&gt;127.9&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_srt_MinimumMember"
      decimals="2"
      id="Fact000922"
      unitRef="USDPShares">1.20</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_srt_MaximumMember"
      decimals="2"
      id="Fact000924"
      unitRef="USDPShares">1.24</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_srt_MinimumMember"
      decimals="2"
      id="Fact000926"
      unitRef="USDPShares">0.45</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_srt_MaximumMember"
      decimals="2"
      id="Fact000928"
      unitRef="USDPShares">0.78</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-12-31_srt_MinimumMember"
      decimals="2"
      id="Fact000930"
      unitRef="USDPShares">1.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-12-31_srt_MaximumMember"
      decimals="2"
      id="Fact000932"
      unitRef="USDPShares">1.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2022-12-31_srt_MinimumMember"
      decimals="2"
      id="Fact000934"
      unitRef="USDPShares">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2022-12-31_srt_MaximumMember"
      decimals="2"
      id="Fact000936"
      unitRef="USDPShares">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000938"
      unitRef="Pure">0.0383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000940"
      unitRef="Pure">0.0442</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000942"
      unitRef="Pure">0.0232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000944"
      unitRef="Pure">0.0358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-01to2023-12-31" id="Fact000946">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31" id="Fact000948">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000950"
      unitRef="Pure">1.331</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000952"
      unitRef="Pure">1.336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000954"
      unitRef="Pure">1.253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000956"
      unitRef="Pure">1.279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000958">&lt;p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zaHcaYHmaBOb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the
following table.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zWVm1EW9sx5a" style="display: none"&gt;SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zPHTUfWKVGv5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20221231_zj8rGqHETkD6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zDSJmr7xVtl8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_z8t61S4MTrn6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Selling and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zkeC21OcHEN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;258,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;323,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zLZg7zNi2ph6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;292,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;354,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zzYW8bSwWdn8" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Stock based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;292,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;354,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000960"
      unitRef="USD">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact000961"
      unitRef="USD">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      id="Fact000963"
      unitRef="USD">28000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      id="Fact000964"
      unitRef="USD">25000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000966"
      unitRef="USD">258000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact000967"
      unitRef="USD">323000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000969"
      unitRef="USD">292000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000970"
      unitRef="USD">354000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact000972"
      unitRef="USD">292000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact000973"
      unitRef="USD">354000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000975"
      unitRef="USD">123000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2023-01-01to2023-12-31" id="Fact000977">P0Y11M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-06-14"
      decimals="INF"
      id="Fact000979"
      unitRef="Shares">12500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2022-06-14" id="Fact000981">2029-06-14</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-06-14"
      decimals="INF"
      id="Fact000983"
      unitRef="USDPShares">20.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-06-132022-06-14"
      decimals="-3"
      id="Fact000985"
      unitRef="USD">135000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-09-30"
      decimals="INF"
      id="Fact000987"
      unitRef="Shares">12500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-09-292022-09-30"
      decimals="0"
      id="Fact000989"
      unitRef="USD">135000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-11-29"
      decimals="INF"
      id="Fact000991"
      unitRef="Shares">18000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000993"
      unitRef="Shares">2906977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000995"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_A1WarrantsMember"
      decimals="INF"
      id="Fact000997"
      unitRef="Shares">2906977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2023-08-302023-08-30_custom_A1WarrantsMember"
      decimals="INF"
      id="Fact000999"
      unitRef="USDPShares">1.47</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_A2WarrantsMember"
      decimals="INF"
      id="Fact001001"
      unitRef="Shares">2906977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2023-08-302023-08-30_custom_A2WarrantsMember"
      decimals="INF"
      id="Fact001003"
      unitRef="USDPShares">1.47</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-08-302023-08-30_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001005"
      unitRef="Shares">8540931</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember"
      id="Fact001007">2029-03-01</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember"
      id="Fact001009">2024-10-01</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_WainwrightMember"
      decimals="INF"
      id="Fact001011"
      unitRef="Shares">218023</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="AsOf2023-08-30_custom_WainwrightMember"
      decimals="INF"
      id="Fact001013"
      unitRef="USDPShares">2.15</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="From2023-08-302023-08-30_custom_WainwrightMember"
      id="Fact001015">2029-03-01</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <NAOV:ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001017">&lt;p id="xdx_893_ecustom--ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock_z4WHOPXwO2u7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
estimating the warrants&#x2019; fair value, the Company used the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zntZVCIjzloj" style="display: none"&gt;SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Risk free interest&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zPSM0kkdCU8a" title="Warrants, measurement input, percentage"&gt;3.49&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zc4BFqlvwVNe" title="Warrants, measurement input, percentage"&gt;0.34&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z3rSXmAGrMHe" title="Warrants, measurement input, percentage"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zh61Njy3Jt93" title="Warrants, measurement input, percentage"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zEqt4fmmmtgf" title="Warrants, measurement input, percentage"&gt;147.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zyCq4Saf5nFk" title="Warrants, measurement input, percentage"&gt;60.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Contractual term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231_zMtzR3hQAEy1" title="Contractual term (in years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231_zCrINF3wfYR1" title="Contractual term (in years)"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</NAOV:ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001019"
      unitRef="Pure">3.49</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001021"
      unitRef="Pure">0.34</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001023"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001025"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001027"
      unitRef="Pure">147.6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001029"
      unitRef="Pure">60.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2023-12-31" id="Fact001031">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31" id="Fact001033">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001035">&lt;p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z9Vp5YaeRglb" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zGwujhMpJKVe"&gt;SCHEDULE OF WARRANTS ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zKTBmul4B60j" style="width: 16%; text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;115,467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zsxWxXAhOpwj" style="text-align: right" title="Warrants, Granted"&gt;30,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zfs3ECAcZDl3" style="text-align: right" title="Warrants, Expired"&gt;(55,215&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zcICGpmD13mi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Canceled"&gt;(12,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z7OIxMkvly3b" style="text-align: right" title="Warrants, Outstanding - Beginning balance"&gt;78,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z5iZiciNXeCd" style="text-align: right" title="Warrants, Granted"&gt;8,758,954&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zpWtZzayOS8h" style="text-align: right" title="Warrants, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1049"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z1Y991JR6Mc3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Canceled"&gt;(203,977&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding &#x2013; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zRiHkVV0GT9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding - Ending balance"&gt;8,633,229&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001037"
      unitRef="Shares">115467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001039"
      unitRef="Shares">30500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001041"
      unitRef="Shares">55215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001043"
      unitRef="Shares">12500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001045"
      unitRef="Shares">78252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001047"
      unitRef="Shares">8758954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001051"
      unitRef="Shares">203977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      id="Fact001053"
      unitRef="Shares">8633229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001055">&lt;p id="xdx_80C_eus-gaap--LesseeOperatingLeasesTextBlock_z5O1HJfwWyul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7 &#x2013; &lt;span id="xdx_82B_zx8TLk6chMm3"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has operating lease agreements with terms up to &lt;span id="xdx_902_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zP7IrMBDsqGl" title="Lease term"&gt;1&lt;/span&gt;-&lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_zSxL1p2hOU2a" title="Lease term"&gt;3&lt;/span&gt; years, including car and office space leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s weighted-average remaining lease term relating to its operating leases is &lt;span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zDX4vk0ROO8k" title="Weighted-average remaining lease term"&gt;0.25&lt;/span&gt; years, with a weighted-average discount
rate of &lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zJgqjPOR5JHe" title="Weighted-average discount rate"&gt;10&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company incurred $&lt;span id="xdx_903_eus-gaap--OperatingLeaseExpense_c20230101__20231231_zPcJKLQbgTvb" title="Operating lease, expense"&gt;70,000&lt;/span&gt; of lease expense for its operating leases for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zoGppllVfaca" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the amount and timing of liabilities arising from the Company&#x2019;s operating leases as
of December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_za3aUuG4dwUa" style="display: none"&gt;SCHEDULE
OF LIABILITIES ARISING FROM OPERATING LEASES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20231231_zFLVLRTefij1" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzL7T_zXiVW0RDdnt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzL7T_zntSeN9Lde6l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total undiscounted operating lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zIrgBWWRSbV1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iI_z0yTn3aizsub" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z28Nm7S8RSpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2023-12-31_srt_MinimumMember"
      id="Fact001057">P1Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2023-12-31_srt_MaximumMember"
      id="Fact001059">P3Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-12-31" id="Fact001061">P0Y3M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001063"
      unitRef="Pure">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001065"
      unitRef="USD">70000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001067">&lt;p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zoGppllVfaca" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the amount and timing of liabilities arising from the Company&#x2019;s operating leases as
of December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_za3aUuG4dwUa" style="display: none"&gt;SCHEDULE
OF LIABILITIES ARISING FROM OPERATING LEASES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20231231_zFLVLRTefij1" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzL7T_zXiVW0RDdnt8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzL7T_zntSeN9Lde6l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total undiscounted operating lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_zIrgBWWRSbV1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiability_iI_z0yTn3aizsub" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001069"
      unitRef="USD">6000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001071"
      unitRef="USD">6000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001073"
      unitRef="USD">1000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001075"
      unitRef="USD">5000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001077">&lt;p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_zMYgWNoqvaL7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8 - &lt;span id="xdx_82F_zflIsj9ImDj2"&gt;LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per common share (&#x201c;Basic EPS&#x201d;) is computed by dividing net loss available to common shareholders by the weighted
average number of common shares outstanding during the period. All outstanding share options and warrants for the years ended December
31, 2023 and 2022 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive
for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zDtgWECkriCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s securities, in common share equivalents, which have been excluded from the calculation
of dilutive loss per share as their effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zgYbTjzpPxI4" style="display: none"&gt;SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_z7BgmnZ7oVk7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220101__20221231_zv5l7PohmsK3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsEmployeeAndNonEmployeeMember_z8j2bggDSeYe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Stock options - employee and non-employee&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;112,685&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;147,619&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zdECo2EzJZw8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,633,229&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78,252&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zvKSE0xOE35" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,745,915&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;225,871&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zIKpWyP5Zv7c" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Dilutive loss per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,745,915&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;225,871&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A1_zVOuS8aQ1HE3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
diluted loss per share equals basic loss per share in the year ended December 31, 2023 and 2022 because the Company had a net loss and
the impact of the assumed exercise of stock options and the vesting of restricted stock would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001079">&lt;p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zDtgWECkriCl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s securities, in common share equivalents, which have been excluded from the calculation
of dilutive loss per share as their effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zgYbTjzpPxI4" style="display: none"&gt;SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_z7BgmnZ7oVk7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220101__20221231_zv5l7PohmsK3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsEmployeeAndNonEmployeeMember_z8j2bggDSeYe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Stock options - employee and non-employee&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;112,685&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;147,619&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zdECo2EzJZw8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,633,229&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78,252&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zvKSE0xOE35" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,745,915&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;225,871&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zIKpWyP5Zv7c" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Dilutive loss per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,745,915&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;225,871&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_StockOptionsEmployeeAndNonEmployeeMember"
      decimals="INF"
      id="Fact001081"
      unitRef="Shares">112685</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_StockOptionsEmployeeAndNonEmployeeMember"
      decimals="INF"
      id="Fact001082"
      unitRef="Shares">147619</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001084"
      unitRef="Shares">8633229</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001085"
      unitRef="Shares">78252</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001087"
      unitRef="Shares">8745915</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001088"
      unitRef="Shares">225871</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001090"
      unitRef="Shares">8745915</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001091"
      unitRef="Shares">225871</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001093">&lt;p id="xdx_80C_eus-gaap--SegmentReportingDisclosureTextBlock_zwh9jN8q8Xs2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 - &lt;span id="xdx_820_zcE9JE7nN78f"&gt;GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Summary
information about geographic areas:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company manages its business on the basis of one reportable segment and derives revenues from selling its products directly to patients
as well as through distributor agreements. The following is a summary of revenues within geographic areas:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zqo2KmMnjHSi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B7_znPceDQA8LE3" style="display: none"&gt;SUMMARY
OF REVENUE WITHIN GEOGRAPHIC AREAS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_zoFoue2saoeb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220101__20221231_z16W5mIxFcz" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--US_zdzXzilvW5K6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,162,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;710,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__srt--EuropeMember_zacLO7TUcQGb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Europe&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--AU_zEEfztPO3tai" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Australia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--IL_zCdnTJrjVmef" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Israel&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1107"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--IN_zWUKL4Emu3h9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;India&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1109"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__custom--OtherCountryMember_zzTlqrSCP7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_z3gFcgQORukf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,283,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;752,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_zulapuReXx0i" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Revenues geographic areas&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,283,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;752,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AB_zmHxFnp2yE28" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s long-lived assets are all located in Israel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year end December 31, 2023, the Company generated approximately &lt;span id="xdx_901_eus-gaap--Revenues_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_z03jgaDKxGd6" title="Revenues"&gt;$917,800&lt;/span&gt; in revenue from its major distributor, UPPI.
This represents approximately &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_zA4BA1fHaZQ8" title="Concentration risk, percentage"&gt;40&lt;/span&gt;% of the company&#x2019;s total revenue for the year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001095">&lt;p id="xdx_894_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zqo2KmMnjHSi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B7_znPceDQA8LE3" style="display: none"&gt;SUMMARY
OF REVENUE WITHIN GEOGRAPHIC AREAS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20231231_zoFoue2saoeb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220101__20221231_z16W5mIxFcz" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--US_zdzXzilvW5K6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;2,162,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;710,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__srt--EuropeMember_zacLO7TUcQGb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Europe&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--AU_zEEfztPO3tai" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Australia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--IL_zCdnTJrjVmef" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Israel&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1107"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--IN_zWUKL4Emu3h9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;India&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1109"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__custom--OtherCountryMember_zzTlqrSCP7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_z3gFcgQORukf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,283,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;752,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0d_zulapuReXx0i" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Revenues geographic areas&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,283,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;752,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_country_US"
      decimals="-3"
      id="Fact001097"
      unitRef="USD">2162000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_country_US"
      decimals="-3"
      id="Fact001098"
      unitRef="USD">710000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_srt_EuropeMember"
      decimals="-3"
      id="Fact001100"
      unitRef="USD">101000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_srt_EuropeMember"
      decimals="-3"
      id="Fact001101"
      unitRef="USD">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_country_AU"
      decimals="-3"
      id="Fact001103"
      unitRef="USD">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_country_AU"
      decimals="-3"
      id="Fact001104"
      unitRef="USD">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_country_IL"
      decimals="-3"
      id="Fact001106"
      unitRef="USD">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_country_IN"
      decimals="-3"
      id="Fact001110"
      unitRef="USD">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_OtherCountryMember"
      decimals="-3"
      id="Fact001113"
      unitRef="USD">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001115"
      unitRef="USD">2283000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001116"
      unitRef="USD">752000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001118"
      unitRef="USD">2283000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001119"
      unitRef="USD">752000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember"
      decimals="0"
      id="Fact001121"
      unitRef="USD">917800</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember"
      decimals="INF"
      id="Fact001123"
      unitRef="Pure">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001125">&lt;p id="xdx_80B_eus-gaap--OtherAssetsDisclosureTextBlock_zlbaEnCArjcf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 &#x2013; &lt;span id="xdx_82E_zp2neVvNpqZ1"&gt;OTHER ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 9, 2020, pursuant to a licensing agreement entered into in March 2020, the Company received &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zCQMcvy7okQ1" title="Warrants and rights outstanding term"&gt;10&lt;/span&gt;-year warrants to purchase &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zJtcr9m5vS4b" title="Warrants issued to purchase common stock"&gt;127,000&lt;/span&gt;
shares of Sanuwave Health, Inc. at a price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zonFbdGhFY6f" title="Exercise price of warrants per share"&gt;0.19&lt;/span&gt; per share. The fair value for warrants received is estimated at the date of grant
using a Black-Scholes-Merton pricing model with the following underlying assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_ecustom--ScheduleOfWarrantsAssumptionsTableTextBlock_zTtAadFnd3Tk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zIRkMrLdbUBl" style="display: none"&gt;SCHEDULE
OF WARRANTS ASSUMPTIONS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Price at valuation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z3CSCOgaKJOa" title="Warrants and rights outstanding, measurement input"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zuYf2VeQwWti" title="Warrants and rights outstanding, measurement input"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z0QUmVVsFDq6" title="Warrants and rights outstanding, measurement input"&gt;0.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zdjuhIeIFC7d" title="Warrants and rights outstanding, measurement input"&gt;0.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zS1KPWHDc5Hk" title="Warrants and rights outstanding, measurement input"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zSjzVkat0Rp" title="Warrants and rights outstanding, measurement input"&gt;3.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zA1i3TOzIF98" title="Expected term (in years)"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zB6jc5xTBTO4" title="Expected term (in years)"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z1YxxRg2kgxc" title="Warrants and rights outstanding, measurement input"&gt;147.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zZJkbvgQFC3d" title="Warrants and rights outstanding, measurement input"&gt;155.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zoaiqH4Wt0P4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers this to be Level 3 inputs and is valued at each reporting period. The fair value of these warrants for the years ended
December 31, 2023 and 2022 was $&lt;span id="xdx_906_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iI_c20231231_zFqhKhCSRUoe" title="Warrants leaving balance"&gt;1,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iI_c20221231_zgE3PGXkDoB8" title="Warrants leaving balance"&gt;3,000&lt;/span&gt;, respectively. There was a net $&lt;span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231_zqNDropwTifh" title="Fair value of warrants"&gt;2,000&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231_zKSmPujF1n28" title="Fair value of warrants"&gt;16,000&lt;/span&gt; change in fair value during the year ended December
31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Financial
Liabilities Measured at Fair Value on a Recurring Basis&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants
would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own
    assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers between Level 3 during the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zX5LsgVQkUQ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents changes in Level 3 asset and liability measured at fair value for the years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BD_zLJKLmlSUQrj" style="display: none"&gt;SCHEDULE
OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Balance &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3d_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zrogXk354dSe" style="width: 14%; text-align: right" title="Balance beginning"&gt;19,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zXkmkxqpALK3" style="width: 14%; text-align: right" title="Balance beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1167"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_pn3d_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_ztb8cxV9Svo3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(16,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zghMgqcxlink" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1171"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3d_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_za1usN4wgDl2" style="text-align: right" title="Balance beginning"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zVyAxVbfZ6Zh" style="text-align: right" title="Balance beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1175"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_pn3d_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zZYmq0kK7k2i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(2,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zRQwGtSf9fu1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1179"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance &#x2013; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3d_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zthq1hzU0W5a" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending"&gt;1,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zgcLr0OMWVbh" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1183"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zYWbp1NwXFui" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z99h2vrqqKck" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the Company&#x2019;s assets and liabilities which are measured at fair value on a recurring basis by level
within the fair value hierarchy:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zimfHPorm8Zg" style="display: none"&gt;SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zKA1pjQNIqv6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zT9FBh0ujqDi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4dLZ0yXrwd7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zHxdkF1GBD3d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Asset:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherAssetsNoncurrent_iI_pn3d_zBA3VzQ9GNs6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 44%; text-align: left"&gt;Other assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1187"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1188"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zYdCA7mNMXn9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHErwdTjVJB7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFwt7MmfeUWf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20221231_z9h01ZHyg4X3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Asset:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherAssetsNoncurrent_iI_pn3d_z6lWVhyqQtN8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 44%; text-align: left"&gt;Other assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1192"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1193"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zQOMlLgGCgwk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember"
      id="Fact001127">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001129"
      unitRef="Shares">127000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001131"
      unitRef="USDPShares">0.19</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001133">&lt;p id="xdx_896_ecustom--ScheduleOfWarrantsAssumptionsTableTextBlock_zTtAadFnd3Tk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zIRkMrLdbUBl" style="display: none"&gt;SCHEDULE
OF WARRANTS ASSUMPTIONS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Price at valuation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z3CSCOgaKJOa" title="Warrants and rights outstanding, measurement input"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zuYf2VeQwWti" title="Warrants and rights outstanding, measurement input"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z0QUmVVsFDq6" title="Warrants and rights outstanding, measurement input"&gt;0.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zdjuhIeIFC7d" title="Warrants and rights outstanding, measurement input"&gt;0.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zS1KPWHDc5Hk" title="Warrants and rights outstanding, measurement input"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zSjzVkat0Rp" title="Warrants and rights outstanding, measurement input"&gt;3.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zA1i3TOzIF98" title="Expected term (in years)"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zB6jc5xTBTO4" title="Expected term (in years)"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z1YxxRg2kgxc" title="Warrants and rights outstanding, measurement input"&gt;147.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zZJkbvgQFC3d" title="Warrants and rights outstanding, measurement input"&gt;155.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001135"
      unitRef="USDPShares">0.01</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001137"
      unitRef="USDPShares">0.02</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001139"
      unitRef="Pure">0.19</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001141"
      unitRef="Pure">0.19</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001143"
      unitRef="Pure">3.88</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001145"
      unitRef="Pure">3.96</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001147">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-12-31_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001149">P8Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001151"
      unitRef="Pure">147.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      id="Fact001153"
      unitRef="Pure">155.6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001155"
      unitRef="USD">1000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001157"
      unitRef="USD">3000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001159"
      unitRef="USD">2000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001161"
      unitRef="USD">16000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001163">&lt;p id="xdx_890_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zX5LsgVQkUQ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents changes in Level 3 asset and liability measured at fair value for the years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BD_zLJKLmlSUQrj" style="display: none"&gt;SCHEDULE
OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Balance &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3d_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zrogXk354dSe" style="width: 14%; text-align: right" title="Balance beginning"&gt;19,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zXkmkxqpALK3" style="width: 14%; text-align: right" title="Balance beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1167"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_pn3d_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_ztb8cxV9Svo3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(16,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zghMgqcxlink" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1171"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3d_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_za1usN4wgDl2" style="text-align: right" title="Balance beginning"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zVyAxVbfZ6Zh" style="text-align: right" title="Balance beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1175"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_pn3d_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zZYmq0kK7k2i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(2,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zRQwGtSf9fu1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1179"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance &#x2013; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3d_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zthq1hzU0W5a" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending"&gt;1,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zgcLr0OMWVbh" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1183"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2021-12-31_custom_DerivativeAssetMember"
      decimals="-3"
      id="Fact001165"
      unitRef="USD">19000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_custom_DerivativeAssetMember"
      decimals="-3"
      id="Fact001169"
      unitRef="USD">-16000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2022-12-31_custom_DerivativeAssetMember"
      decimals="-3"
      id="Fact001173"
      unitRef="USD">3000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_custom_DerivativeAssetMember"
      decimals="-3"
      id="Fact001177"
      unitRef="USD">-2000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2023-12-31_custom_DerivativeAssetMember"
      decimals="-3"
      id="Fact001181"
      unitRef="USD">1000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001185">&lt;p id="xdx_894_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z99h2vrqqKck" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the Company&#x2019;s assets and liabilities which are measured at fair value on a recurring basis by level
within the fair value hierarchy:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zimfHPorm8Zg" style="display: none"&gt;SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zKA1pjQNIqv6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zT9FBh0ujqDi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4dLZ0yXrwd7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zHxdkF1GBD3d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Asset:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherAssetsNoncurrent_iI_pn3d_zBA3VzQ9GNs6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 44%; text-align: left"&gt;Other assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1187"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1188"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zYdCA7mNMXn9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zHErwdTjVJB7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFwt7MmfeUWf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20221231_z9h01ZHyg4X3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Asset:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherAssetsNoncurrent_iI_pn3d_z6lWVhyqQtN8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 44%; text-align: left"&gt;Other assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1192"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1193"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001189"
      unitRef="USD">1000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001190"
      unitRef="USD">1000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001194"
      unitRef="USD">3000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001195"
      unitRef="USD">3000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001197">&lt;p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zMPmn4nDCo1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11 - &lt;span id="xdx_821_z5ZZxul3KcO1"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Pending
and settled litigation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 26, 2021, Protrade Systems, Inc. (&#x201c;Protrade&#x201d;) filed a Request for Arbitration (the &#x201c;Request&#x201d;) with the
International Court of Arbitration (the &#x201c;ICA&#x201d;) of the International Chamber of Commerce alleging the Company is in breach
of an Exclusive Distribution Agreement dated March 7, 2019 (the &#x201c;Exclusive Distribution Agreement&#x201d;) between Protrade and
the Company. Protrade alleges, in part, that the Company has breached the Exclusive Distribution Agreement by discontinuing the manufacture
of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $&lt;span id="xdx_906_eus-gaap--LossContingencyDamagesSoughtValue_pn6n6_c20210225__20210226_znqTcJwOCfD7" title="Litigation damages sought value"&gt;3&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 15, 2022, the arbitrator issued a final award, which, determined that (i) the Company had the right to terminate the Exclusive
Distribution Agreement; (ii) the Company did not breach the duty of good faith and fair dealing with regard to the Exclusive Distribution
Agreement; and (iii) the Company did not breach any confidentiality obligations to Protrade. Nevertheless, the arbitrator determined
that the Company did not comply with the obligation to supply Protrade with a year&#x2019;s supply of patches, and awarded Protrade $&lt;span id="xdx_90F_eus-gaap--LossContingencyDamagesSoughtValue_c20220314__20220315_zxiKeYax9QRj" title="Loss contingency damages sought value"&gt;1,500,250&lt;/span&gt;,
which consists of $&lt;span id="xdx_905_eus-gaap--LossContingencyDamagesAwardedValue_c20220314__20220315_zNKtBobuEkhl" title="Loss contingency damages sought value"&gt;1,432,000&lt;/span&gt; for &#x201c;lost profits&#x201d; and $&lt;span id="xdx_902_eus-gaap--LossContingencyDamagesPaidValue_c20220314__20220315_zsk6beRAMUCh" title="Loss contingency damages paid value"&gt;68,250&lt;/span&gt; as reimbursement of arbitration costs, on the grounds that the
Company allegedly failed to supply Protrade with certain patches utilized by users of DV0057 Painshield MD device. The arbitrator based
the decision on the testimony of Protrade&#x2019;s president who asserted that a user would use in excess of 33 patches per each device.
The Company believes that the number of patches per device alleged by Protrade is grossly inflated, and that these claims were not properly
raised before the arbitrator. Accordingly, on April 13, 2022, the Company submitted an application for the correction of the award which
the arbitrator denied on June 22, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 22, 2022, the Company filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority,
that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular,
the Company averred in its motion that Protrade&#x2019;s witness made false statements in arbitration, and that the arbitrator resolved
a claim that was never raised by Protrade and that has no factual basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 3, 2022, the court issued a decision granting Protrade its petition to confirm the award and denying the cross-motion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 9, 2022, the Company filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newer
information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate
Division, Second Department. On March 21, 2023, the court denied the motion to re-argue and renew.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 10, 2023, the Company filed its appeal with the Appellate Division, Second Department. That appeal is now fully briefed and is awaiting
the scheduling of oral argument.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023 and 2022, the Company accrued the amount of the arbitration award to Protrade of approximately $&lt;span id="xdx_90D_eus-gaap--LossContingencyDamagesAwardedValue_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--ArbitratorMember_zAiMGaumE9Gd" title="Damages awarded value"&gt;2.0&lt;/span&gt; million and
$&lt;span id="xdx_902_eus-gaap--LossContingencyDamagesAwardedValue_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ArbitratorMember_zbtX1O2xFph6" title="Damages awarded value"&gt;1.9&lt;/span&gt;
million, respectively, including interest which is classified in &#x201c;Other accounts payable and accrued expenses&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Other
Risks&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 12, 2020, the World Health Organization declared COVID-19 to be a pandemic, and the COVID-19 pandemic has resulted in significant
financial market volatility and uncertainty. A continuation or worsening of the levels of market disruption and volatility seen in the
recent past could have an adverse effect on our ability to access capital, on our business, results of operations and financial condition,
and on the market price of our common shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2021-02-252021-02-26"
      decimals="-6"
      id="Fact001199"
      unitRef="USD">3000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2022-03-142022-03-15"
      decimals="0"
      id="Fact001201"
      unitRef="USD">1500250</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="From2022-03-142022-03-15"
      decimals="0"
      id="Fact001203"
      unitRef="USD">1432000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="From2022-03-142022-03-15"
      decimals="0"
      id="Fact001205"
      unitRef="USD">68250</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="From2023-01-012023-12-31_custom_ArbitratorMember"
      decimals="-5"
      id="Fact001207"
      unitRef="USD">2000000.0</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="From2022-01-012022-12-31_custom_ArbitratorMember"
      decimals="-5"
      id="Fact001209"
      unitRef="USD">1900000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001211">&lt;p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zIjJShY1duNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12 &#x2013; &lt;span id="xdx_82A_zHwbRkgSaXH"&gt;RELATED PARTY TRANSACTION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
firm of FisherBroyles LLP is handled all our Protrade litigation and appeals through December 31, 2023. For the year ended December 31, 2023, we have been
billed and paid legal fees from FisherBroyles amounting to $&lt;span id="xdx_90F_eus-gaap--LegalFees_c20230101__20231231_zEXT5N5xiECg" title="Legal fees paid"&gt;360,000&lt;/span&gt;
and recorded as part of &#x201c;General and administrative expenses&#x201d; in the condensed consolidated statements of operations. As
has been previously disclosed, one of our board members, Aurora Cassirer, is a partner at FisherBroyles. Ms. Cassirer does not
provide any legal services or legal advice to the Company&lt;b&gt;.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;On January 1, 2024 Ms. Cassirer and the lawyers responsible for handling our Protrade litigation left the firm of
FisherBroyles to join the firm of Pierson Ferdinand LLP. As of January1, 2024, the firm Pierson Ferdinand is the sole firm handling all
our Protrade litigation and appeals. As was the case in prior years, Ms. Cassirer does not provide any legal services or legal advice
to the Company&lt;b&gt;.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:LegalFees
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001213"
      unitRef="USD">360000</us-gaap:LegalFees>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001215">&lt;p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_zhnRXkk19X8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
13 &#x2013; &lt;span id="xdx_829_zFqjyTiizYM2"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the U.S. Company had federal and state net operating loss carry forward for tax purposes of approximately $&lt;span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zwNvhNYgHS1d" title="Net operating loss carry forward"&gt;39,000,000&lt;/span&gt;
and $&lt;span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zBJ3Etrohua2" title="Net operating loss carry forward"&gt;5,900,000&lt;/span&gt;, respectively. $&lt;span id="xdx_907_ecustom--FederalNetOperatingLossCarriedForward_iI_c20231231_zwNRj25Hqmd2" title="Federal net operating loss carried forward"&gt;24,600,000&lt;/span&gt; of the federal net operating loss can be carried forward indefinitely but can only offset up to 80%
of taxable income in a given year, and $&lt;span id="xdx_903_ecustom--FederalNetOperatingLossOffsetAgainstTaxableIncome_c20230101__20231231_zIrNOuvDo2l7" title="Federal net operating loss offset against taxable income"&gt;14,000,000&lt;/span&gt; of the federal net operating loss can be used to fully offset taxable income in the period
it is utilized but can only be carried forward for &lt;span id="xdx_903_ecustom--OperatingLossCarryforwardsExpirationTerm_dtY_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zCOkawHqAZgj" title="Operating loss carryforwards expiration term"&gt;20&lt;/span&gt; years. Utilization of the U.S. net operating losses may be subject to substantial
limitations in the event of a change of ownership under the provisions of the Internal Revenue Code of 1986. The Company has not performed
an analysis, but the potential impact of any limitation would not be material to the financial statements due to the fact that the respective
DTAs are fully offset by a valuation allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zxnbso5R5Mma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax expense is comprised of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_z2ZEgTJkfCf" style="display: none"&gt;SCHEDULE
OF PROVISION FOR INCOME TAXES EXPENSES&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zmjvbgZhslVa" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_zPtEMduEogxl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Year ended December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current Tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzPkK_z4RqDBYbuIN" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1229"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1230"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzPkK_zYgKagFT9lcj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1232"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1233"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBzPkK_z3vqFA82Rcvh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; width: 64%"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;(25,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;37,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzPkK_maOTEBzPz3_zzizTUKRDohi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;37,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred Tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzsCS_z7i3AF1pfaP4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,226,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,545,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzsCS_zrYhNfF8dWZh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(43,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;653,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBzsCS_zUXTTSlbiAgc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzsCS_maOTEBzPz3_zKzaWQHbaMj4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,267,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(893,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--ValuationAllowanceOfIncomeTaxExpenseBenefit_iN_di_msOTEBzPz3_zd5Oh5rAmiH1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Less: Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,267,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;893,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherTaxExpenseBenefit_iT_mtOTEBzPz3_zF36SxoUBa19" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Total Tax&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(25,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;37,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_z7572ar9jUR2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also recognized approximately $&lt;span id="xdx_90F_ecustom--FranchiseFees_c20230101__20231231_zOQjh27Wy9Zk" title="Franchise fees"&gt;4,000&lt;/span&gt; of state franchise fees during the year ended December 31, 2023. The difference between
the statutory tax rate of the Company and the effective tax rate is primarily the result of tax benefits generated by the Company
and its subsidiary which have not been recognized due to the uncertainty that such tax benefits will ultimately be realized. A
reconciliation of the statutory U.S Federal rate to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zpteC3ITByUc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B9_zSMdrfrg3T57" style="display: none"&gt;SCHEDULE
OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20231231_zbHuUe6pTmVj" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20221231_zIOeR5A1F7wh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maETR_zmiGa1aiqgvl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal income tax benefit at statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maETR_zcs7v0iGQRl6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-12.06&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_maETR_zVxv4WWZWJtd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.10&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.03&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_maETR_zm4fVvutvmPf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Permanent Items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.63&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.61&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maETR_zJ5QBZhAxHeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-33.54&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-16.61&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_maETR_zJRgSKFsSCV9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Return to provision adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.54&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationForfeitedOptions_pid_dp_maETR_z75SgzRX3xU2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Forfeited options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_maETR_z2VItOcgCqx1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.09&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtETR_zl7k8330V6db" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.06&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0.68&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zh9RZBocYL5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Foreign
tax&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax
rates applicable to the income of the Israeli subsidiary:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Israeli corporate tax rate in 2023 and 2022 is &lt;span id="xdx_90C_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20230101__20231231__srt--StatementGeographicalAxis__country--IL_zGDGZbyIGcVj" title="Corporate tax rate"&gt;&lt;span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20220101__20221231__srt--StatementGeographicalAxis__country--IL_z8gPwftECnLi" title="Corporate tax rate"&gt;23&lt;/span&gt;&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
subsidiary has final tax assessments through 2017.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
before taxes:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zbSKXBsx6D68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zXIsO0DQqpGg" style="display: none"&gt;SCHEDULE
OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231_z8mWiloTgFB7" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231_zqK12mFzxOmj" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOz5C4_zyOvfAfFMcIh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,785,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;5,557,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_iN_di_maILFCOz5C4_z62yXclGJFS3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(103,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(144,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iNT_pp0d_di_mtILFCOz5C4_zkl7rWZhAPK4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss before taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,682,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,413,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zlh9rxjh8iG8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Deferred
income taxes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial
purposes and the amounts used for income tax purposes. Significant components of the Company&#x2019;s deferred tax assets are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zrP1Lo8MXCHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zC3Cfioj7gj" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_zEZn4j6B6AZe" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20221231_zs9kOnKtWmJ6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzNu2_znnSWeasyhbl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net operating loss carry forward&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;8,486,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;7,306,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccruals_iI_maDTAGzNu2_z7NXq4QFfZae" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Arbitration accrual&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;414,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;414,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_maDTAGzNu2_zwKOuU1dq8ad" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Stock compensation and other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;570,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;483,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzNu2_maDTALNzt1d_zrxAOuIKgRDe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,470,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,203,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzt1d_zQ9rsp0VmYdj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,470,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,203,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzt1d_zNUvIjeFkC22" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1322"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1323"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zKS7LL9aM81d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2023 and 2022, the net increase in valuation allowance of $&lt;span id="xdx_90E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230101__20231231_zT6BXiTIKPR7" title="Net increases in valuation allowance"&gt;1,267,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zpBloM1RXdM4" title="Net increases in valuation allowance"&gt;894,000&lt;/span&gt;, respectively, was primarily driven
by the increase in net operating loss carry forwards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of
the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which
temporary differences are deductible and net operating losses are able to be utilized. Based on consideration of these factors, the Company
concluded that all of its recorded deferred tax assets are not more likely than not realizable and recorded a full valuation allowance
at December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers the earnings of its non-U.S. subsidiary to be indefinitely invested outside the United States on the basis of estimates
that future domestic cash generation will be sufficient to meet future domestic cash needs and our specific plans for reinvestment of
those subsidiary earnings. We have not recorded a deferred tax liability related to the U.S. federal and state income taxes as an estimate
of undistributed earnings of foreign subsidiaries would not be practicable to estimate at this time. If the Company does decide to repatriate
the foreign earnings, we would need to adjust our income tax provision in the period we determined that the earnings will no longer be
indefinitely invested outside the United States.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Reconciliation
of the theoretical tax expense to the actual tax expense&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits
from accumulated net operating loss carry forward among the Company and its subsidiary due to the uncertainty of the realization of such
tax benefits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the
statement of operations. As of December 31, 2023 and 2022, the Company does not have any liabilities recorded for uncertain tax positions
and does not expect there to be any events which could potentially result in the need for a material liability to be recorded. There
were no changes in the Company&#x2019;s unrecognized tax benefits during the years ended December 31, 2023 and 2022. The Company did not
recognize any interest or penalties during fiscal 2023 or 2022 related to unrecognized tax benefits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S.
federal and New York State income taxes are open for examination for years 2020-2023 and Israel tax returns are open for examination
for years 2019-2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="Fact001217"
      unitRef="USD">39000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      id="Fact001219"
      unitRef="USD">5900000</us-gaap:OperatingLossCarryforwards>
    <NAOV:FederalNetOperatingLossCarriedForward
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001221"
      unitRef="USD">24600000</NAOV:FederalNetOperatingLossCarriedForward>
    <NAOV:FederalNetOperatingLossOffsetAgainstTaxableIncome
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001223"
      unitRef="USD">14000000</NAOV:FederalNetOperatingLossOffsetAgainstTaxableIncome>
    <NAOV:OperatingLossCarryforwardsExpirationTerm
      contextRef="From2023-01-012023-12-31_us-gaap_DomesticCountryMember"
      id="Fact001225">P20Y</NAOV:OperatingLossCarryforwardsExpirationTerm>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001227">&lt;p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zxnbso5R5Mma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax expense is comprised of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_z2ZEgTJkfCf" style="display: none"&gt;SCHEDULE
OF PROVISION FOR INCOME TAXES EXPENSES&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zmjvbgZhslVa" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_zPtEMduEogxl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Year ended December 31,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current Tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBzPkK_z4RqDBYbuIN" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1229"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1230"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBzPkK_zYgKagFT9lcj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1232"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1233"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentForeignTaxExpenseBenefit_maCITEBzPkK_z3vqFA82Rcvh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; width: 64%"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;(25,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;37,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBzPkK_maOTEBzPz3_zzizTUKRDohi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(25,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;37,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred Tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzsCS_z7i3AF1pfaP4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,226,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,545,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzsCS_zrYhNfF8dWZh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(43,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;653,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_maDITEBzsCS_zUXTTSlbiAgc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzsCS_maOTEBzPz3_zKzaWQHbaMj4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,267,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(893,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--ValuationAllowanceOfIncomeTaxExpenseBenefit_iN_di_msOTEBzPz3_zd5Oh5rAmiH1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Less: Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,267,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;893,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OtherTaxExpenseBenefit_iT_mtOTEBzPz3_zF36SxoUBa19" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Total Tax&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(25,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;37,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001235"
      unitRef="USD">-25000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001236"
      unitRef="USD">37000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001238"
      unitRef="USD">-25000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001239"
      unitRef="USD">37000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001241"
      unitRef="USD">-1226000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001242"
      unitRef="USD">-1545000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001244"
      unitRef="USD">-43000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001245"
      unitRef="USD">653000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001247"
      unitRef="USD">2000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001248"
      unitRef="USD">-1000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001250"
      unitRef="USD">-1267000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001251"
      unitRef="USD">-893000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <NAOV:ValuationAllowanceOfIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001253"
      unitRef="USD">-1267000000</NAOV:ValuationAllowanceOfIncomeTaxExpenseBenefit>
    <NAOV:ValuationAllowanceOfIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001254"
      unitRef="USD">-893000000</NAOV:ValuationAllowanceOfIncomeTaxExpenseBenefit>
    <us-gaap:OtherTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001256"
      unitRef="USD">-25000000</us-gaap:OtherTaxExpenseBenefit>
    <us-gaap:OtherTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001257"
      unitRef="USD">37000000</us-gaap:OtherTaxExpenseBenefit>
    <NAOV:FranchiseFees
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001259"
      unitRef="USD">4000</NAOV:FranchiseFees>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001261">&lt;p id="xdx_894_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zpteC3ITByUc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B9_zSMdrfrg3T57" style="display: none"&gt;SCHEDULE
OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20231231_zbHuUe6pTmVj" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20221231_zIOeR5A1F7wh" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maETR_zmiGa1aiqgvl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal income tax benefit at statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_maETR_zcs7v0iGQRl6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-12.06&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_maETR_zVxv4WWZWJtd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.10&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.03&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_maETR_zm4fVvutvmPf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Permanent Items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.63&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.61&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maETR_zJ5QBZhAxHeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-33.54&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-16.61&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_maETR_zJRgSKFsSCV9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Return to provision adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.54&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationForfeitedOptions_pid_dp_maETR_z75SgzRX3xU2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Forfeited options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_maETR_z2VItOcgCqx1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.09&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_mtETR_zl7k8330V6db" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.06&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0.68&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001263"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001264"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001266"
      unitRef="Pure">0.0113</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001267"
      unitRef="Pure">-0.1206</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001269"
      unitRef="Pure">-0.0010</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001270"
      unitRef="Pure">-0.0003</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <NAOV:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001272"
      unitRef="Pure">-0.0063</NAOV:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <NAOV:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001273"
      unitRef="Pure">-0.0061</NAOV:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001275"
      unitRef="Pure">-0.3354</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001276"
      unitRef="Pure">-0.1661</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001278"
      unitRef="Pure">0.1220</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001279"
      unitRef="Pure">0.0754</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <NAOV:EffectiveIncomeTaxRateReconciliationForfeitedOptions
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001281"
      unitRef="Pure">0.0000</NAOV:EffectiveIncomeTaxRateReconciliationForfeitedOptions>
    <NAOV:EffectiveIncomeTaxRateReconciliationForfeitedOptions
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001282"
      unitRef="Pure">0.0000</NAOV:EffectiveIncomeTaxRateReconciliationForfeitedOptions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001284"
      unitRef="Pure">-0.0001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001285"
      unitRef="Pure">0.0009</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001287"
      unitRef="Pure">0.0006</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001288"
      unitRef="Pure">-0.0068</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31_country_IL"
      decimals="INF"
      id="Fact001290"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31_country_IL"
      decimals="INF"
      id="Fact001292"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001294">&lt;p id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zbSKXBsx6D68" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zXIsO0DQqpGg" style="display: none"&gt;SCHEDULE
OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231_z8mWiloTgFB7" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231_zqK12mFzxOmj" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOz5C4_zyOvfAfFMcIh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;3,785,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;5,557,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_iN_di_maILFCOz5C4_z62yXclGJFS3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(103,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(144,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iNT_pp0d_di_mtILFCOz5C4_zkl7rWZhAPK4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss before taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,682,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,413,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001296"
      unitRef="USD">3785000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001297"
      unitRef="USD">5557000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact001299"
      unitRef="USD">103000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact001300"
      unitRef="USD">144000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001302"
      unitRef="USD">-3682000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001303"
      unitRef="USD">-5413000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001305">&lt;p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zrP1Lo8MXCHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zC3Cfioj7gj" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_zEZn4j6B6AZe" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20221231_zs9kOnKtWmJ6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzNu2_znnSWeasyhbl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net operating loss carry forward&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;8,486,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;7,306,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccruals_iI_maDTAGzNu2_z7NXq4QFfZae" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Arbitration accrual&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;414,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;414,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_maDTAGzNu2_zwKOuU1dq8ad" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Stock compensation and other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;570,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;483,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzNu2_maDTALNzt1d_zrxAOuIKgRDe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,470,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,203,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzt1d_zQ9rsp0VmYdj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,470,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,203,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzt1d_zNUvIjeFkC22" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1322"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1323"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001307"
      unitRef="USD">8486000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001308"
      unitRef="USD">7306000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <NAOV:DeferredTaxAssetsTaxDeferredExpenseAccruals
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001310"
      unitRef="USD">414000000</NAOV:DeferredTaxAssetsTaxDeferredExpenseAccruals>
    <NAOV:DeferredTaxAssetsTaxDeferredExpenseAccruals
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001311"
      unitRef="USD">414000000</NAOV:DeferredTaxAssetsTaxDeferredExpenseAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001313"
      unitRef="USD">570000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001314"
      unitRef="USD">483000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001316"
      unitRef="USD">9470000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001317"
      unitRef="USD">8203000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001319"
      unitRef="USD">9470000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001320"
      unitRef="USD">8203000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001325"
      unitRef="USD">1267000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001327"
      unitRef="USD">894000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001329">&lt;p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_z0ClMVdiAMQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
14 - &lt;span id="xdx_825_zPmiuDvVvpLh"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 1, 2024, the Company signed a new lease agreement in Nesher, Israel for &lt;span id="xdx_901_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20240301__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIKsilRSUE79" title="Lease term"&gt;36&lt;/span&gt; months with payments of approximately $&lt;span id="xdx_906_eus-gaap--OperatingLeasePayments_c20240301__20240301__us-gaap--LeaseContractualTermAxis__custom--LeaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRHKyA0MElmh" title="Lease payments"&gt;2,500&lt;/span&gt; per month.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;In March 2024, we entered into a contract with Veranex, Inc., to provide
certain research and development services to assist with the development of the company&#x2019;s next generation of UroShield and PainShield
products. The Agreement has a term of approximately &lt;span id="xdx_901_ecustom--ResearchAndDevelopmentTermOfContract_iI_dtW_c20240301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--VeranexIncMember_zZlfdlfEiXQ3" title="Research and development, term of contract"&gt;50&lt;/span&gt; weeks, subject to adjustments or earlier termination thereof in accordance with
the terms of the Agreement, with estimated fees and expenses of up to approximately $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_pn5n6_c20240301__20240301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--VeranexIncMember_zuHkSEWK7The" title="Research and development expenses"&gt;1.1&lt;/span&gt; million subject to certain adjustments, including
among other things, revising the agreement in the event of changing assumptions or facts, unforeseen development deviations, or changes
in scope.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="AsOf2024-03-01_custom_LeaseAgreementMember_us-gaap_SubsequentEventMember"
      id="Fact001331">P36M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-03-012024-03-01_custom_LeaseAgreementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001333"
      unitRef="USD">2500</us-gaap:OperatingLeasePayments>
    <NAOV:ResearchAndDevelopmentTermOfContract
      contextRef="AsOf2024-03-01_us-gaap_SubsequentEventMember_custom_VeranexIncMember"
      id="Fact001335">P350D</NAOV:ResearchAndDevelopmentTermOfContract>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="From2024-03-012024-03-01_us-gaap_SubsequentEventMember_custom_VeranexIncMember"
      decimals="-5"
      id="Fact001337"
      unitRef="USD">1100000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
</xbrl>
